var title_f21_37_22096="Jet ventilator settings";
var content_f21_37_22096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Initial jet ventilator settings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 427px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If the patient was hypoxic with controlled mechanical ventilation, driving pressure should be adjusted as necessary to achieve a mean airway pressure equal to that present during controlled mechanical ventilation. If minute ventilation under those conditions is not at least equal to that present during controlled mechanical ventilation, driving pressure should be further increased until this condition is met before obtaining arterial blood gas levels. If the patient was hypercapnic with controlled mechanical ventilation, driving pressure should be adjusted as necessary to achieve a minute ventilation two times that present during controlled mechanical ventilation. If mean airway pressure exceeds 110 percent of that present during controlled mechanical ventilation before obtaining that minute ventilation, arterial blood gas levels should be obtained at that point before further increasing driving pressure. In individual patients, changes in rate may have opposite effects on PaCO2.",
"     <br>",
"      &bull; Careful monitoring of peak, mean, and end-expiratory airway pressure as well as minute ventilation and oximetry should be performed when any change is made in ventilatory parameters. Only experienced personnel should use high-frequency jet ventilation.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Standiford, TJ, Morganroth, ML, Chest 1989; 96:1383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22096=[""].join("\n");
var outline_f21_37_22096=null;
var title_f21_37_22097="Intermediate case 3 with answer";
var content_f21_37_22097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prolonged QT interval due to hypocalcemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 99px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The QT interval in this case is quite prolonged (0.50 sec) at a heart rate of 55 beats/min. The rate corrected QT (QTc) interval can be calculated from: QT interval &divide; sqrt (RR interval). The RR interval is 1.05 sec leading to a QTc of 0.48 sec which is longer than the normal value of &le;0.44 sec. A long QT interval with a \"stretched out\" ST segment and normal T wave is most consistent with hypocalcemia. In contrast, hypercalcemia shortens the QT, hyponatremia usually has no effect on the ECG, and hypokalemia prolongs repolarization with flattened or broad T waves and prominent U waves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22097=[""].join("\n");
var outline_f21_37_22097=null;
var title_f21_37_22098="Allergy to penicillin and related antibiotics";
var content_f21_37_22098=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/37/22098/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22098/contributors\" id=\"au2058\">",
"       Roland Solensky, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/37/22098/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22098/contributors\" id=\"se944\">",
"       N Franklin Adkinson, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/37/22098/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22098/contributors\" id=\"de128\">",
"       Anna M Feldweg, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?21/37/22098?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      PENICILLIN ALLERGY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Serious allergies to penicillin are common, with about 10 percent of people reporting an allergy. However, most people who believe they are allergic can take penicillin without a problem, either because they were never truly allergic or because their allergy to penicillin has resolved over time.",
"    </p>",
"    <p>",
"     People who have a remote history of allergic reaction to a medication may become less allergic as time passes. Only about 20 percent of people will be allergic to penicillin 10 years after their initial allergic reaction if they are not exposed to it again during this time period.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS PENICILLIN?",
"     </span>",
"    </p>",
"    <p>",
"     Penicillin is one of the most commonly prescribed antibiotics. It is part of a family of antibiotics known as beta lactams, and there are many individual medications in this family: Penicillin G, nafcillin, oxacillin, cloxacillin and dicloxacillin, ampicillin, amoxicillin, carbenicillin, ticarcillin, and piperacillin.",
"    </p>",
"    <p>",
"     Anyone who is allergic to one of the penicillins should be presumed to be allergic to all penicillins and should avoid the entire group, unless they have been specifically evaluated for this problem.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      REACTIONS TO PENICILLIN",
"     </span>",
"    </p>",
"    <p>",
"     A variety of unexpected reactions can occur after taking penicillin. When reporting past problems with antibiotics, it is important to provide as much detail as possible about the reaction.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Adverse reactions",
"     </span>",
"     &nbsp;&mdash;&nbsp;\"Adverse reaction\" is the medical term for any undesirable reaction caused by a medication. Both",
"     <strong>",
"      allergic",
"     </strong>",
"     and",
"     <strong>",
"      nonallergic",
"     </strong>",
"     adverse reactions can occur. Nonallergic reactions are much more common. Examples of common nonallergic adverse reactions include upset stomach and diarrhea.",
"    </p>",
"    <p>",
"     It is important to distinguish nonallergic adverse reactions from true allergic reactions. Some people report that they are allergic to penicillin when actually they have had a nonallergic side effect. As a result, the person may be treated for a particular infection with a less effective or more toxic antibiotic. This can lead to antibiotic failure or resistance, which can be costly and prolong illness.",
"    </p>",
"    <p>",
"     Anyone who is uncertain if a past allergic reaction was truly caused by allergy should avoid the antibiotic until they have discussed the situation with their healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Rashes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several different types of rashes can appear while people are taking a penicillin medication:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Rashes that involve hives (raised, intensely itchy spots that come and go over hours), or occur with other allergic symptoms like wheezing or swelling of the skin or throat, suggest a true allergy (",
"       <a class=\"graphic graphic_picture graphicRef79242 \" href=\"UTD.htm?7/41/7824\">",
"        picture 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Rashes that are flat, blotchy, spread over days but do not change by the hour are less likely to represent a dangerous allergy (",
"       <a class=\"graphic graphic_picture graphicRef70062 \" href=\"UTD.htm?31/30/32239\">",
"        picture 2",
"       </a>",
"       ). These rashes typically start after several days of treatment.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     It can be difficult to distinguish between different types of rashes that occurred in the past. Taking a photograph of a rash is always helpful.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Allergic reactions",
"     </span>",
"     &nbsp;&mdash;&nbsp;An allergic reaction occurs when the immune system begins to recognize a drug as something \"foreign\". Several different symptoms can indicate that a person is allergic to penicillin. These include hives (raised, intensely itchy spots that come and go over hours) (",
"     <a class=\"graphic graphic_picture graphicRef79242 \" href=\"UTD.htm?7/41/7824\">",
"      picture 1",
"     </a>",
"     ), angioedema (swelling of the tissue under the skin, commonly around the face), throat tightness, wheezing, coughing, and trouble breathing from asthma-like reactions (narrowing of the airways into the lungs).",
"    </p>",
"    <p>",
"     A past history of these types of reactions is important because the person might develop a more severe reaction, such as anaphylaxis, if they were to take the antibiotic again. Mild to moderate allergic reactions to penicillins occur in 1 to 5 percent of people.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Anaphylaxis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anaphylaxis is a sudden, potentially life-threatening allergic reaction. Symptoms include those of an allergic reaction, as well as very low blood pressure, difficulty breathing, abdominal pain, swelling of the throat or tongue,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     diarrhea or vomiting. Fortunately, anaphylaxis is uncommon. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"      \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      PENICILLIN ALLERGY TESTING",
"     </span>",
"    </p>",
"    <p>",
"     Skin testing for penicillin allergy is the most reliable way to determine if a person is truly allergic to penicillin. Approximately ninety percent of people will test negative (meaning they do NOT have a penicillin allergy), because they either lost the allergy over time, or they were never allergic in the first place. There are some situations in which penicillin, which is generally safe and inexpensive, would be a suitable antibiotic, but a person with possible allergy is given a stronger drug with more side effects because their allergic status is unclear. Therefore, determining if someone can safely take penicillin can be useful.",
"    </p>",
"    <p>",
"     Testing for penicillin allergy is especially important in the following situations:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       People who have a suspected penicillin (or closely related antibiotic) allergy and require penicillin to treat a life-threatening condition for which no alternate antibiotic is appropriate.",
"      </li>",
"      <li>",
"       People who have frequent infections and have suspected allergies to many antibiotics, leaving few options for treatment.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Penicillin skin testing does NOT provide any information about certain types of reactions. This includes severe reactions with extensive blistering and peeling of the skin (Stevens-Johnson syndrome or toxic epidermal necrolysis), a widespread sunburn-like reaction that later peeled (erythroderma) or a rash composed of small bulls-eyes or target-like spots (erythema multiforme). People with these types of reactions should never again be given the medication that caused the reaction. This applies to all situations since a second exposure could cause a severe progressive reaction and even death.",
"    </p>",
"    <p>",
"     Skin testing should be done by an allergist in an office or hospital setting. Testing usually takes about one hour to complete. The skin is pricked and injected with weak solutions of the various preparations of penicillin and observed for a reaction. This may cause discomfort due to itching, although it is not painful.",
"    </p>",
"    <p>",
"     A positive skin reaction is an itchy, red bump that lasts about half an hour and then resolves. A positive test indicates that the person is truly allergic. People with a positive test should continue to avoid penicillins.",
"    </p>",
"    <p>",
"     If the patient completes the skin testing without a positive reaction, a single oral dose of full strength penicillin is commonly given to confirm that the patient does not have an allergy to the medication. The oral dose is needed because medical tests, including skin testing, are rarely 100 percent accurate. About three percent or less of people with a history of penicillin allergy and a negative skin test will still experience an allergic reaction. However, these reactions are very mild. If a person has a negative skin test and has no reaction to an oral dose of the antibiotic, no future precautions are necessary.",
"    </p>",
"    <p>",
"     If skin testing is NOT available, options for people who may be allergic to penicillin include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Take a different antibiotic",
"      </li>",
"      <li>",
"       Undergo a challenge test (see",
"       <a class=\"local\" href=\"#H12\">",
"        'Challenge testing'",
"       </a>",
"       below)",
"      </li>",
"      <li>",
"       Undergo desensitization (see",
"       <a class=\"local\" href=\"#H13\">",
"        'Penicillin desensitization'",
"       </a>",
"       below)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Challenge testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;If skin testing is not available, a healthcare provider may recommend a challenge test. However, this is only recommended if the person requires penicillin, no other antibiotic is available, and the chances of a true allergy are small (eg, last reaction was at least 10 years ago or allergic reaction symptoms not likely caused by true allergy). If the chances of a true allergy are high, desensitization is generally recommended.",
"    </p>",
"    <p>",
"     Challenge testing is usually done in an office setting, starting with a very small dose of the antibiotic given by mouth. If the person tolerates the smallest dose, a larger dose is given every 30 to 60 minutes until",
"     <span class=\"nowrap\">",
"      he/she",
"     </span>",
"     has signs of an allergic reaction or the full dose is given. If the person tolerates the full dose, he or she is not allergic to the antibiotic.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      PENICILLIN DESENSITIZATION",
"     </span>",
"    </p>",
"    <p>",
"     Desensitization can be done for people who are truly allergic to penicillin, but require treatment with it or a closely related antibiotic. Desensitization refers to a process of giving a medication in a controlled and gradual manner, which allows the person to tolerate it temporarily without an allergic reaction.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Technique",
"     </span>",
"     &nbsp;&mdash;&nbsp;Desensitization can be performed with oral or intravenous medications, but should always be performed by an allergy specialist. There are different techniques for desensitization. Some patients undergo desensitization in an outpatient clinic under supervision while others are treated in an intensive care unit.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Limitations",
"     </span>",
"     &nbsp;&mdash;&nbsp;While usually successful, desensitization has two important limitations.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Desensitization does not work and must never be attempted for certain types of reactions (such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythroderma, erythema multiforme, and some others). Desensitization also does not work for other types of immunologic reactions to antibiotics, such as serum sickness, drug fever, or hemolytic anemia.",
"      </li>",
"      <li>",
"       Desensitization is",
"       <strong>",
"        temporary",
"       </strong>",
"       . A person is unlikely to have an allergic reaction to the medication during treatment, after undergoing desensitization, as long as the antibiotic is taken regularly. However, once the antibiotic is stopped for more than 24 hours (times differ slightly for different medications), the person is again at risk for a sudden allergic reaction. Repeat desensitization is required if the same medication is needed again.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      OTHER ANTIBIOTIC ALLERGIES",
"     </span>",
"    </p>",
"    <p>",
"     Reliable skin tests are not commercially available for some antibiotics. Thus, determining if a person has an allergy to these antibiotics is more difficult, and is mostly based on the history of the reaction. Skin testing with other antibiotics is sometimes performed, but the results are much less certain than those of penicillin testing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Cephalosporins",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cephalosporins are a class of antibiotics closely related to penicillin. There are a number of cephalosporin medications available, a few of which include cephalexin (Keflex&reg;), cefaclor (Ceclor&reg;), cefuroxime (Ceftin&reg;), cefadroxil (Duricef&reg;) , cephradine (Velocef&reg;). cefprozil (Cefzil&reg;), loracarbef (Lorabid&reg;), ceftibuten (Cedax&reg;), cefdinir (Omnicef&reg;), cefditoren (Spectracef&reg;), cefpodoxime (Vantin&reg;) and cefixime (Suprax&reg;).",
"    </p>",
"    <p>",
"     People with a",
"     <strong>",
"      history",
"     </strong>",
"     of penicillin allergy have a small risk of having an allergic reaction to cephalosporins. If possible, penicillin skin testing should be performed in these individuals. Since testing will be negative in about 90 percent of these people, a negative test will allow them to take cephalosporins safely. People with a",
"     <strong>",
"      positive skin test",
"     </strong>",
"     to penicillin have a small risk of an allergic reaction to cephalosporins and may require more caution in terms of how the cephalosporin is administered.",
"    </p>",
"    <p>",
"     Allergic reactions to cephalosporins are less common than reactions to penicillin. In addition, skin testing to evaluate cephalosporin allergy is not as accurate as penicillin skin testing. If a cephalosporin is required, then there are several options:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Take a different antibiotic",
"      </li>",
"      <li>",
"       Undergo a challenge test (see",
"       <a class=\"local\" href=\"#H12\">",
"        'Challenge testing'",
"       </a>",
"       above)",
"      </li>",
"      <li>",
"       Undergo desensitization (see",
"       <a class=\"local\" href=\"#H13\">",
"        'Penicillin desensitization'",
"       </a>",
"       above)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804590351\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12676285\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=see_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1523?source=see_link\">",
"      Patient information: Angioedema (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/12/12483?source=see_link\">",
"      Patient information: What you should know about antibiotics (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/24/42370?source=see_link\">",
"      Patient information: Allergy skin testing (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/3/23603?source=see_link\">",
"      Patient information: Drug allergy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12676304\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"      Allergy to penicillins",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link\">",
"      Fatal anaphylaxis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=see_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Allergy Asthma and Immunology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.aaaai.org/patients/publicedmat/tips/adversereactions.stm\">",
"        www.aaaai.org/patients/publicedmat/tips/adversereactions.stm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/003519.htm\">",
"        www.nlm.nih.gov/medlineplus/ency/article/003519.htm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Mayo Clinic",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.mayoclinic.com/health/penicillin-allergy/DS00620\">",
"        www.mayoclinic.com/health/penicillin-allergy/DS00620",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?21/37/22098/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 12, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?21/37/22098?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22098/abstract/1\">",
"      Solensky R, Earl HS, Gruchalla RS. Clinical approach to penicillin-allergic patients: a survey. Ann Allergy Asthma Immunol 2000; 84:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22098/abstract/2\">",
"      Solensky R. Drug desensitization. Immunol Allergy Clin North Am 2004; 24:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22098/abstract/3\">",
"      Forrest DM, Schellenberg RR, Thien VV, et al. Introduction of a practice guideline for penicillin skin testing improves the appropriateness of antibiotic therapy. Clin Infect Dis 2001; 32:1685.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f21_37_22098=[""].join("\n");
var outline_f21_37_22098=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           PENICILLIN ALLERGY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS PENICILLIN?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           REACTIONS TO PENICILLIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           PENICILLIN ALLERGY TESTING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           PENICILLIN DESENSITIZATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           OTHER ANTIBIOTIC ALLERGIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\" title=\"picture 1\">",
"           Hives PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/30/32239\" title=\"picture 2\">",
"           Morbilliform eruption 2",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f21_37_22099="Potassium bicarbonate and potassium chloride (effervescent): Drug information";
var content_f21_37_22099=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium bicarbonate and potassium chloride (effervescent): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/13/23764?source=see_link\">",
"    see \"Potassium bicarbonate and potassium chloride (effervescent): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/3/37938?source=see_link\">",
"    see \"Potassium bicarbonate and potassium chloride (effervescent): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Electrolyte Supplement, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypokalemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention: 16-24 mEq/day in 2-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment: 40-100 mEq/day in 2-4 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2913644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/3/37938?source=see_link\">",
"      see \"Potassium bicarbonate and potassium chloride (effervescent): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Oral: 1-4 mEq/kg/24 hours in divided doses as required to maintain normal serum potassium",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F211718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet for solution, oral [effervescent]: Potassium chloride 25 mEq [potassium bicarbonate 0.5 g and potassium chloride 1.5 g]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F211706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals; solution should be sipped slowly, over 5-10 minutes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment or prevention of hypokalemia",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F211727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Gastrointestinal: Abdominal discomfort, diarrhea, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F211708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; hyperkalemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI effects: May cause GI upset (eg, nausea, vomiting, diarrhea, abdominal pain, discomfort) and lead to GI ulceration, bleeding, perforation and/or obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acid/base disorders: Use with caution in patients with acid/base alterations; changes in serum potassium concentrations can occur during acid/base correction, monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering conditions/disorders: Use with caution in patients with disorders or conditions likely to contribute to altered serum potassium and hyperkalemia (eg, untreated Addison's disease, heat cramps, severe tissue breakdown from trauma or burns).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium concentrations closely with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Digitalis: Use with caution in digitalized patients; may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering therapies: Use with caution in patients receiving concomitant medications or therapies that increase potassium (eg, ACEI, potassium-sparing diuretics, potassium containing salt substitutes).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May enhance the adverse/toxic effect of Potassium Chloride. This is specific to solid oral dosage forms of potassium chloride. Management: Concurrent use of solid oral dosage forms of potassium chloride are contraindicated with glycopyrrolate.  Consider using a non-solid oral dosage form or another alternative therapy as appropriate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F211722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F211710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with meals.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F211701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, magnesium (to facilitate potassium repletion), chloride, and bicarbonate",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13203065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reference ranges may vary depending on the laboratory",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum potassium: 3.5-5.2 mEq/L",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Corpotasin CL (MX);",
"     </li>",
"     <li>",
"      Sando-K (GB)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10063 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22099=[""].join("\n");
var outline_f21_37_22099=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211729\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211717\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2913644\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211718\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211703\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211689\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211706\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211705\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211727\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211708\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211692\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299914\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211697\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211699\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287298\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211722\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287299\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211710\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211701\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203065\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539917\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10063\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10063|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/13/23764?source=related_link\">",
"      Potassium bicarbonate and potassium chloride (effervescent): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/3/37938?source=related_link\">",
"      Potassium bicarbonate and potassium chloride (effervescent): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_37_22100="Lichenoid drug eruption 1";
var content_f21_37_22100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lichenoid drug eruption (drug-induced lichen planus)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this patient with a lichenoid drug eruption, flat erythematous papules are typically distributed on the trunk and upper extremities. Grouped and confluent lesions also can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22100=[""].join("\n");
var outline_f21_37_22100=null;
var title_f21_37_22101="Primary cough headache";
var content_f21_37_22101=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary cough headache",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/37/22101/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22101/contributors\">",
"     F Michael Cutrer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/37/22101/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22101/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/37/22101/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22101/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/37/22101/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cough headache is one of several relatively uncommon headache syndromes that may occur either as a primary headache or as a headache secondary to potentially malignant processes. Careful evaluation for underlying causes is important for these uncommon types of headache.",
"   </p>",
"   <p>",
"    This topic will review primary cough headache. Other types of uncommon primary headache disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=see_link\">",
"     \"Primary stabbing headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44356?source=see_link\">",
"     \"Primary exertional headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16054?source=see_link\">",
"     \"Primary headache associated with sexual activity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5700?source=see_link\">",
"     \"Hypnic headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=see_link\">",
"     \"Thunderclap headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16243?source=see_link\">",
"     \"Nummular headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sometimes referred to as benign cough headache or Valsalva maneuver headache, primary cough headache is provoked by coughing or straining in the absence of any intracranial disorder.",
"   </p>",
"   <p>",
"    Primary cough headache most often affects people over the age of 40. Cough headaches are sudden in onset, bilateral in distribution, and last from seconds to 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/1\">",
"     1",
"    </a>",
"    ]. These headaches are not associated with nausea, vomiting, light or sound sensitivity, conjunctival injection, rhinorrhea, or lacrimation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The true prevalence and incidence of primary cough headache is unknown, but one Danish population-based study found that the lifetime prevalence of benign cough headache was 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headaches provoked by coughing may occur either as a benign primary headache disorder or as a secondary headache. The International Headache Society criteria require that structural lesions be ruled out with neuroimaging before the diagnosis of primary cough headache can be made [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several structural lesions have been associated with cough headache, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chiari type 1 malformations with or without syringomyelia [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/4-7\">",
"       4-7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Posterior fossa lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/2,8\">",
"       2,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Unruptured cerebral aneurysms [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intracranial hypervolemia [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intracranial low pressure state (with positional headaches) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Unilateral carotid artery occlusion [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Electrode implantation in the periaqueductal gray [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited evidence suggests that secondary etiologies are present in approximately one-half of patients who have cough-provoked headaches. In one series that included 30 patients who presented with headaches precipitated by coughing, the headaches were secondary to another cause in 17 patients (57 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/7\">",
"     7",
"    </a>",
"    ]. All 17 had a Chiari type I malformation, with cerebellar tonsillar descent of &gt;3 mm below the foramen magnum by MRI. Fourteen of these patients also had signs or symptoms related to the posterior",
"    <span class=\"nowrap\">",
"     fossa/foramen",
"    </span>",
"    magnum region, and five had evidence of syringomyelia.",
"   </p>",
"   <p>",
"    Given these data, we suggest a neuroimaging evaluation, preferably with a contrast-enhanced brain MRI, for all patients presenting with de novo headache precipitated by coughing. We recommend such an evaluation for patients with posterior fossa symptoms or signs. In addition, we recommend a neurovascular evaluation (using CT or MR angiography) of the intracranial and extracranial vessels if the patient has a recent history of unilateral cough-provoked headache with contralateral transient focal neurologic symptoms.",
"   </p>",
"   <p>",
"    A few of the secondary causes of cough-provoked headache are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link\">",
"     \"Unruptured intracranial aneurysms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Distinguishing primary and secondary forms of cough headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical differences may help distinguish between benign primary cough headache and secondary cough headache [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/7\">",
"     7",
"    </a>",
"    ]. These differences include a longer typical duration for secondary cough headache than for the primary form (under one minute for benign headaches versus seconds to days for secondary headaches), and the presence of posterior fossa signs or symptoms in secondary cough headache.",
"   </p>",
"   <p>",
"    A response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    is more typical for primary cough headache than for secondary forms. However, the lack of response to indomethacin is probably not reliable as a sole distinguishing feature for secondary cough headache, since the cough headache associated with Chiari I malformation may respond to indomethacin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, headaches that occur in the context of other primary disorders, such as migraine, cluster headache, and hemicrania continua, may be intensified by coughing or Valsalva maneuvers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/2\">",
"     2",
"    </a>",
"    ]. The presence of associated symptoms suggestive of other primary headache disorders allows them to be distinguished from primary cough headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Distinguishing cough headache and exertional headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because Valsalva maneuvers frequently occur in the context of many forms of physical exertion, it is sometimes difficult to distinguish primary cough headache from primary exertional headache. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44356?source=see_link\">",
"     \"Primary exertional headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, several clinical differences between benign cough and benign exertional headache have been identified that aid in distinguishing the two disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cough headache is triggered by Valsalva maneuvers, while exertional headache is triggered by more sustained physical exercise",
"     </li>",
"     <li>",
"      The average age of patients afflicted with benign cough headache is 67 (&plusmn; 11), while the average age of patients with benign exertional headache is 24 (&plusmn; 11)",
"     </li>",
"     <li>",
"      Primary cough headache typically has a faster onset than benign exertional headache, which builds up over minutes or longer",
"     </li>",
"     <li>",
"      Primary cough headaches are shorter than benign exertional headaches",
"     </li>",
"     <li>",
"      Primary cough headaches are typically sharp and stabbing in quality while benign exertional headaches are described as pulsatile",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of primary cough headache is poorly understood. One postulated mechanism is that coughing induces sudden increases in intra-abdominal and intrathoracic pressures that are transmitted through the valveless venous system into the intracranial venous sinus system, causing activation of intradural or perivascular nociceptive neurons.",
"   </p>",
"   <p>",
"    In support of this hypothesis, one investigator measured cerebrospinal fluid pressure from the lumbar region and the cisterna magna during coughing in 16 patients requiring cervical myelography [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/15\">",
"     15",
"    </a>",
"    ]. None of the cases were found to have complete blockage of the spinal subarachnoid space. During a cough, there was a phase during which the lumbar pressure exceeded the cisternal, followed by a phase in which the cisternal pressure exceeded the lumbar. Thus, on coughing, the intrathoracic and intra-abdominal pressure caused a pressure wave that was transmitted into the head and then rapidly downwards again [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies suggest that the upward passage of fluid from the spine towards the head is relatively unimpeded, but that the downward rebound from the head towards the spine is sufficient to cause tissue to jam in the foramen magnum. This creates a pressure gradient between the head and spine, termed the \"craniospinal pressure dissociation\" [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/15\">",
"     15",
"    </a>",
"    ]. However, cough and Valsalva maneuvers that occur in the course of daily life are usually insufficient to activate intracranial nociceptive fibers, suggesting that patients with cough headache have some factor (or factors) that lowers activation thresholds and results in recurrent depolarization of the nociceptive fibers.",
"   </p>",
"   <p>",
"    One study found stenotic abnormalities on magnetic resonance venography in 5 of 7 patients with primary cough headache, compared with 0 of 16 headache-free control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/16\">",
"     16",
"    </a>",
"    ]. This finding suggests that venous outflow obstruction could be a promoting factor in some patients with primary cough headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for spontaneous recovery is fair at best. In the first reported series of 21 cases, nine had spontaneous recovery within 18 months to 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/17\">",
"     17",
"    </a>",
"    ]. Two additional patients had improvement after lumbar puncture. Another two had relief after tooth extraction. The remaining patients continued to have cough headache until they were lost to follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;First, any pulmonary disease causing chronic coughing should be identified and treated if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link\">",
"     \"Evaluation of subacute and chronic cough in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27913?source=see_link\">",
"     \"Treatment of subacute and chronic cough in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of choice for primary cough headache is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    . A small, double-blind, controlled study found that indomethacin (150 mg daily) was effective treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/19\">",
"     19",
"    </a>",
"    ]. In other series, indomethacin doses up to 250 mg per day have been required [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     Indomethacin",
"    </a>",
"    decreases intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/21\">",
"     21",
"    </a>",
"    ], and that may be why it is effective in this condition as compared with other nonsteroidal antiinflammatory drugs. Because of the strong potential for gastrointestinal irritation with chronic indomethacin use, the addition of a proton pump inhibitor is probably prudent in those patients requiring long-term indomethacin treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients may lose their tendency for cough headache with time, suggesting that periodic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    withdrawal after six to 12 months of therapy is also wise.",
"   </p>",
"   <p>",
"    Other medications reported to be effective for primary cough headache in open-label trials or case series include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/10\">",
"     10",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/22\">",
"     22",
"    </a>",
"    ], methysergide [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/23\">",
"     23",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/24\">",
"     24",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/213?source=see_link\">",
"     ergonovine",
"    </a>",
"    , intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     dihydroergotamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"     phenelzine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to medical therapy, several authors have reported occasional benefit from cerebrospinal fluid removal by lumbar puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/17,26\">",
"     17,26",
"    </a>",
"    ]. One author reported that patients who have been unresponsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    may improve after high volume (40 mL) cerebrospinal fluid removal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22101/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary cough headache most often affects people older than age 40 and is provoked by coughing or straining in the absence of any intracranial disorder. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients presenting with de novo headache precipitated by coughing, we suggest a neuroimaging evaluation, preferably with a contrast-enhanced brain MRI. We recommend such an evaluation for patients who have posterior fossa symptoms or signs. In addition, we recommend a neurovascular evaluation with CT or MR angiography of the intracranial and extracranial vessels if the patient has a recent history of unilateral cough-provoked headache with contralateral transient focal neurologic symptoms.(See",
"      <a class=\"local\" href=\"#H3\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because Valsalva maneuvers frequently occur in the context of many forms of physical exertion, it is sometimes difficult to distinguish primary cough headache from primary exertional headache. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Distinguishing cough headache and exertional headache'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with primary cough headache, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      (150 to 250 mg daily) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternative medications that may be effective include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      , methysergide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/213?source=see_link\">",
"       ergonovine",
"      </a>",
"      , intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"       dihydroergotamine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"       phenelzine",
"      </a>",
"      . Any pulmonary disease causing chronic coughing should be identified and treated if possible. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/1\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     Ekbom, K. Cough headache. In: Headache. Handbook of clinical neurology, Rose, FC (Ed), Elsevier Science Publishers, Amsterdam 1986. p.367.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/3\">",
"      Rasmussen BK, Olesen J. Symptomatic and nonsymptomatic headaches in a general population. Neurology 1992; 42:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/4\">",
"      Williams B. Cough headache due to craniospinal pressure dissociation. Arch Neurol 1980; 37:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/5\">",
"      Nightingale S, Williams B. Hindbrain hernia headache. Lancet 1987; 1:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/6\">",
"      Ertsey C, Jelencsik I. Cough headache associated with Chiari type-I malformation: responsiveness to indomethacin. Cephalalgia 2000; 20:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/7\">",
"      Pascual J, Iglesias F, Oterino A, et al. Cough, exertional, and sexual headaches: an analysis of 72 benign and symptomatic cases. Neurology 1996; 46:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/8\">",
"      Eross EJ, Swanson JW, Krauss WE, Parisi JE. A rare cause of cough headache in an adult. Headache 2002; 42:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/9\">",
"      Smith WS, Messing RO. Cerebral aneurysm presenting as cough headache. Headache 1993; 33:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/10\">",
"      Wang SJ, Fuh JL, Lu SR. Benign cough headache is responsive to acetazolamide. Neurology 2000; 55:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/11\">",
"      Mokri B. Spontaneous CSF leaks mimicking benign exertional headaches. Cephalalgia 2002; 22:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/12\">",
"      Britton TC, Guiloff RJ. Carotid artery disease presenting as cough headache. Lancet 1988; 1:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/13\">",
"      Rivera M, del Real MA, Teruel JL, et al. Carotid artery disease presenting as cough headache in a patient on haemodialysis. Postgrad Med J 1991; 67:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/14\">",
"      Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache 1987; 27:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/15\">",
"      Williams B. Cerebrospinal fluid pressure changes in response to coughing. Brain 1976; 99:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/16\">",
"      Donnet A, Valade D, Houdart E, et al. Primary cough headache, primary exertional headache, and primary headache associated with sexual activity: a clinical and radiological study. Neuroradiology 2013; 55:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/17\">",
"      SYMONDS C. Cough headache. Brain 1956; 79:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/18\">",
"      Edmeads J. The worst headache ever. 2. Innocuous causes. Postgrad Med 1989; 86:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/19\">",
"      Mathew NT. Indomethacin responsive headache syndromes. Headache 1981; 21:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/20\">",
"      Raskin NH. The cough headache syndrome: treatment. Neurology 1995; 45:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/21\">",
"      Slavik RS, Rhoney DH. Indomethacin: a review of its cerebral blood flow effects and potential use for controlling intracranial pressure in traumatic brain injury patients. Neurol Res 1999; 21:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/22\">",
"      Calandre L, Hernandez-Lain A, Lopez-Valdes E. Benign Valsalva's maneuver-related headache: an MRI study of six cases. Headache 1996; 36:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/23\">",
"      Bahra A, Goadsby PJ. Cough headache responsive to methysergide. Cephalalgia 1998; 18:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/24\">",
"      Mateo I, Pascual J. Coexistence of chronic paroxysmal hemicrania and benign cough headache. Headache 1999; 39:437.",
"     </a>",
"    </li>",
"    <li>",
"     Raskin, NH. The indomethacin-responsive syndromes. In: Headache, 2nd ed, Churchill Livingstone, New York 1988. p.255.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22101/abstract/26\">",
"      Rooke ED. Benign exertional headache. Med Clin North Am 1968; 52:801.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3325 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22101=[""].join("\n");
var outline_f21_37_22101=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Distinguishing primary and secondary forms of cough headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Distinguishing cough headache and exertional headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5700?source=related_link\">",
"      Hypnic headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16243?source=related_link\">",
"      Nummular headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/330?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44356?source=related_link\">",
"      Primary exertional headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16054?source=related_link\">",
"      Primary headache associated with sexual activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=related_link\">",
"      Primary stabbing headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=related_link\">",
"      Thunderclap headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27913?source=related_link\">",
"      Treatment of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=related_link\">",
"      Unruptured intracranial aneurysms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_37_22102="Ethinyl estradiol and drospirenone: Patient drug information";
var content_f21_37_22102=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and drospirenone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/62/42985?source=see_link\">",
"     see \"Ethinyl estradiol and drospirenone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gianvi&trade;;",
"     </li>",
"     <li>",
"      Loryna&trade;;",
"     </li>",
"     <li>",
"      Ocella&trade;;",
"     </li>",
"     <li>",
"      Syeda&trade;;",
"     </li>",
"     <li>",
"      Vestura&trade;;",
"     </li>",
"     <li>",
"      Yasmin&reg;;",
"     </li>",
"     <li>",
"      Yaz&reg;;",
"     </li>",
"     <li>",
"      Zarah&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Yasmin&reg;;",
"     </li>",
"     <li>",
"      Yaz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not smoke while taking birth control pills. Cigarette smoking raises the chance of very bad heart and blood-related side effects. This chance is higher with age (older than 35 years of age) and with heavy smoking (15 or more cigarettes per day). Birth control pills do not stop the spread of diseases caused by having sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat mood problems caused by monthly periods.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691832",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat endometriosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease painful period (menstrual) cycles.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ethinyl estradiol, drospirenone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, high blood sugar with blood vessel disease, diseased arteries in the brain, disease of a heart valve with problems, endometrial cancer, heart disease, high blood pressure, kidney failure, liver disease, liver tumor, poor adrenal function, very bad headache, tumor where estrogen makes it grow, or  vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3415739",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches and are older than 35 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a heavy smoker (more than 15 cigarettes per day) and older than 35 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have not started your period.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you turned yellow during pregnancy or with estrogen-based or hormone contraceptive use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698386",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you miss 2 periods in a row, take a pregnancy test before starting a new dosing cycle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Missed dosing facts may be found in the package insert or call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12445 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22102=[""].join("\n");
var outline_f21_37_22102=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163803\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855144\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027272\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027274\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027273\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027278\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027279\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027281\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027276\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027277\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027282\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027283\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/62/42985?source=related_link\">",
"      Ethinyl estradiol and drospirenone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_37_22103="Glucocorticoid withdrawal";
var content_f21_37_22103=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Glucocorticoid withdrawal",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/37/22103/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22103/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22103/contributors\">",
"     Kenneth G Saag, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/37/22103/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22103/contributors\">",
"     Eric L Matteson, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/37/22103/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22103/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/37/22103/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic glucocorticoid therapy is used in the treatment of a variety of disorders because of its potent antiinflammatory effects and, occasionally, because it is thought to have immunosuppressive activity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/1\">",
"     1",
"    </a>",
"    ]. Among the rheumatic diseases in which glucocorticoids are often used are rheumatoid arthritis, large- and small-vessel vasculitis, systemic lupus erythematosus, polymyalgia rheumatica, and, in some cases, the arthritis associated with inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite its efficacy, steroid-induced side effects generally require tapering of the drug as soon as the disease being treated is under control. Tapering must be done carefully to avoid both recurrent activity of the underlying disease and possible cortisol deficiency resulting from hypothalamic-pituitary-adrenal axis (HPA) suppression during the period of steroid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=see_link&amp;anchor=H18#H18\">",
"     \"Pharmacologic use of glucocorticoids\", section on 'HPA axis suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic discusses the major issues related to tapering, the regimen(s) we use in most patients, and other glucocorticoid tapering regimens that have been reported in the literature.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of adrenal insufficiency are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR WITHDRAWING GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is helpful to briefly review the indications for glucocorticoid withdrawal before discussing the different glucocorticoid withdrawal regimens. These indications include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      When the maximum desired therapeutic benefit has been obtained",
"     </li>",
"     <li>",
"      When inadequate therapeutic benefit has been obtained after an adequate trial",
"     </li>",
"     <li>",
"      When side effects, such as lumbar spine osteoporosis or hypertension, become serious or uncontrollable with medication",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there are two complications that require",
"    <strong>",
"     immediate",
"    </strong>",
"    cessation of glucocorticoids or reduction to a physiologic dose, rather than tapering:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Steroid-induced acute psychosis that is unresponsive to antipsychotic medications",
"     </li>",
"     <li>",
"      Herpesvirus-induced corneal ulceration, which can rapidly lead perforation of the cornea and possibly permanent blindness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If immediate cessation is not possible (eg, because of a critical clinical need), use of the lowest necessary dose, then discontinuing steroids as soon as possible, is strongly advised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID PREPARATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    will be the agent discussed, although other glucocorticoid preparations are available (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"UTD.htm?41/61/42972\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    .) These preparations are available in various strengths (eg, 1, 2, 5, 10, 20 mg for prednisone) and in various formulations (tablet, intravenous preparations, intramuscular preparations, and rectal suppositories). Differences in the absorption or metabolism of these various strengths and formulations could affect the ability to taper steroids. Fortunately, most commercially available prednisone and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    preparations appear to be",
"    <strong>",
"     bioequivalent",
"    </strong>",
"    . This can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In vivo studies using healthy males in a crossover study revealed no statistical difference in any pharmacokinetic parameter with five different oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      preparations [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rectal and oral absorption of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      are equivalent, with the relative bioavailability of oral to rectal administration being 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The systemic bioavailability of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is equivalent to that of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (0.77 to 0.80) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/4\">",
"       4",
"      </a>",
"      ]. Prednisone itself is biologically inactive, but it is rapidly converted to the active form prednisolone. However, patients with severe liver disease may have difficulty converting prednisone to prednisolone; in such patients, it is possible that one might not get the same effect from prednisone as from prednisolone. In addition, certain drug interactions can affect the metabolism and bioavailability of prednisone. As an example, barbiturates,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , attenuate the biological effects of glucocorticoids (",
"      <a class=\"graphic graphic_table graphicRef53228 \" href=\"UTD.htm?16/58/17326\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Steroid pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tapering regimens could potentially be influenced if drug disposition changed at varying",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    doses. Although there is a trend toward dose-dependent kinetics, with larger doses being cleared more rapidly, the effect is relatively small and usually not of great clinical importance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors can influence pharmacokinetics. One interesting study examined 54 patients of varying ages who were given oral and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/8\">",
"     8",
"    </a>",
"    ]. Eleven patients (20 percent) demonstrated unusual kinetics. Their drug clearance was approximately twice that of the rest of the population without an identifiable cause. Other findings included incomplete absorption of glucocorticoids in four patients and an inverse correlation (r = -0.88) between prednisolone clearance and age, which means that a given dose may have a greater effect in older persons. This relation to age has been confirmed in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, prednisolone clearance is also slower in African-Americans compared to Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With this degree of interpatient variability in kinetics, it is conceivable that some patients may show greater withdrawal symptoms than others. This may occur despite the known difference between plasma glucocorticoid kinetics and biologic activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HYPOTHALAMIC-PITUITARY-ADRENAL AXIS SUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of exogenous glucocorticoids can suppress the hypothalamic-pituitary-adrenal axis (HPA). Abrupt cessation, or too rapid withdrawal, of glucocorticoids in such patients may cause symptoms of adrenal insufficiency. HPA suppression and the clinical manifestations of adrenal insufficiency are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=see_link&amp;anchor=H18#H18\">",
"     \"Pharmacologic use of glucocorticoids\", section on 'HPA axis suppression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Identifying patients with HPA suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potency, dose, and duration of glucocorticoid use are important but imperfect predictors of the presence of HPA suppression. A clinical decision about a particular patient's risk of having HPA suppression guides subsequent decision making about glucocorticoid tapering. Patients exposed to glucocorticoids can be classified and managed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients suspected of having HPA suppression who are otherwise candidates for glucocorticoid withdrawal can be cautiously tapered (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Tapering regimens'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Patients determined to have a low risk of clinically significant HPA suppression may have glucocorticoids weaned as dictated by control of disease activity rather than by concern for adrenal insufficiency.",
"     </li>",
"     <li>",
"      Patients for whom the likelihood of HPA suppression is uncertain, but for whom the consequences of developing acute adrenal insufficiency are serious (eg, the patient who is about to undergo major surgery), may benefit from testing of the HPA functional reserve to guide further therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Characteristics of patients who are likely to have HPA suppression and those who are unlikely, or for whom the likelihood of HPA suppression is uncertain, are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=see_link&amp;anchor=H18#H18\">",
"     \"Pharmacologic use of glucocorticoids\", section on 'HPA axis suppression'",
"    </a>",
"    .) The following is a brief summary:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     HPA suppression likely",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have received glucocorticoids who meet the following criteria are presumed to have HPA suppression:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anyone who has received a glucocorticoid dose comparable to more than 20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      a day for more than three weeks",
"     </li>",
"     <li>",
"      Anyone who has received an",
"      <span class=\"nowrap\">",
"       evening/bedtime",
"      </span>",
"      dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      for more than a few weeks",
"     </li>",
"     <li>",
"      Any patient who has a Cushingoid appearance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such patients do not need testing to evaluate their HPA function, but should be treated like any patient with secondary adrenal insufficiency, including the wearing of a medical alert bracelet or necklace and carrying an emergency medical information card. We advise patients on glucocorticoids with presumed HPA suppression to seek immediate medical attention for diagnostic and therapeutic intervention if they develop symptoms of adrenal insufficiency, rather than using self-administered medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     HPA suppression unlikely",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who meet one of the following criteria regarding steroid use are less likely to have a suppressed HPA and therefore may have glucocorticoids weaned as is appropriate for the underlying disease.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A patient who has received any dose of glucocorticoid for less than three weeks",
"     </li>",
"     <li>",
"      Patients treated with alternate-day glucocorticoid therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Intermediate/uncertain risk of HPA suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have an intermediate or uncertain risk of HPA suppression include those with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those taking 10 to 20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      per day for more than three weeks",
"     </li>",
"     <li>",
"      Any patient who has taken less than 10 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or its equivalent per day, providing that it is not taken as a single",
"      <strong>",
"       bedtime",
"      </strong>",
"      dose for more than a few weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If withdrawal from glucocorticoids is otherwise indicated, gradual reduction in dose is appropriate for these patients with an intermediate or uncertain risk of HPA suppression. Such patients do not need to be tested for HPA functional reserve unless abrupt discontinuation is being considered or the patient is facing an acute stress such as surgery. In the latter case, one can give stress doses of glucocorticoids (",
"    <a class=\"graphic graphic_table graphicRef69479 \" href=\"UTD.htm?5/17/5403\">",
"     table 3",
"    </a>",
"    ) or, if time permits, test for the responsiveness of the adrenal with an ACTH (cosyntropin) stimulation test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Estimation of HPA suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying the degree of HPA suppression is not simple clinically. Thus, in practice it is unusual to perform any testing of HPA function prior to beginning the glucocorticoid withdrawal process. However, as noted above, in certain settings (eg, the patient for whom elective surgery is planned) such testing may be warranted.",
"   </p>",
"   <p>",
"    The response to administration of synthetic adrenocorticotropic hormone (ACTH [cosyntropin]) is the preferred method to assess adrenocortical function. Although the cosyntropin test does not provide information about hypothalamic function, it has the advantage that it can be performed in the office or clinic setting over the course of approximately one-hour. Test results should be available within hours to days thereafter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\", section on 'Low dose ACTH test'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\", section on 'Standard high-dose ACTH stimulation test'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\", section on 'Normal values'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Low-dose ACTH stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients who require testing, we use the low-dose ACTH test for initial testing. The low-dose ACTH test and the criteria of a normal adrenal response are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\", section on 'ACTH stimulation tests'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\", section on 'Low dose ACTH test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Corticotropin releasing hormone (CRH) test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The corticotropin releasing hormone (CRH) test can assess both the ACTH and cortisol responses and may be used instead of the cosyntropin test if there is concern about pituitary function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26311?source=see_link\">",
"     \"Corticotropin-releasing hormone stimulation test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other tests either do not address the adrenal response to stress (eg, plasma cortisol or urinary cortisol excretion) or are more time-consuming than is practical for most practice settings (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    stimulation and insulin-induced hypoglycemia tests).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for HPA-axis function is appropriate when patients are using &le; 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and there is difficulty reducing the dose further because of non-disease related symptoms. We prefer the low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    If ACTH stimulation testing indicates normal adrenal responsiveness but a patient continues to have non-disease related symptoms with further attempts to reduce glucocorticoid dosing, then CRH stimulation testing may be used. In our experience, CRH testing is needed on very rare occasions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER FORMS OF GLUCOCORTICOID DEPENDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other forms of steroid dependence (beyond symptomatic and biochemical evidence of HPA suppression) have been identified which can hinder steroid tapering. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Psychologic dependence on steroids",
"     </li>",
"     <li>",
"      Recrudescence of the disease for which the drug was prescribed",
"     </li>",
"     <li>",
"      Symptoms of apparent adrenal insufficiency despite normal HPA function and lack of disease recrudescence",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TAPERING REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of clinical evidence to support any particular regimen of glucocorticoid tapering. Published controlled trial-derived data do not specifically address the issue of weaning patients from long-term moderate or high-dose glucocorticoids in chronic rheumatic or other inflammatory disorders. The following illustrative reviews and selected studies have principally addressed the effect of tapering regimens of different durations have had on the activity of the underlying disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A year 2002 systematic review found nine controlled trials with random patient assignment that compared different glucocorticoid tapering regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/13\">",
"       13",
"      </a>",
"      ]. The published reports reviewed dealt almost exclusively (seven of nine trials) with the treatment of asthma or chronic obstructive pulmonary disease (COPD) exacerbations and generally assessed relapse-rates",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      physiologic measures (such as peak expiratory flow rates, forced expiratory volumes, or oxygen saturation) as patients were weaned from systemic to inhaled glucocorticoids.",
"      <br/>",
"      <br/>",
"      The authors of the review concluded that there was no significant difference between abrupt, rapid, or slow glucocorticoid tapering regimens for these outcomes in asthma or COPD. The other two trials reviewed were 7 week versus 15 week tapering regimens in Crohn disease and 10 versus 21 week tapering in bone marrow transplant patients with graft versus host disease [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Again, in these latter two studies there were no clinically significant differences in outcomes between the shorter and longer tapers.",
"     </li>",
"     <li>",
"      A trial evaluated 46 children with nephrotic syndrome who were treated with high doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/16\">",
"       16",
"      </a>",
"      ]. Tapering was performed over eight weeks or five months. Twenty-nine children in the short taper group received 60",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day for four weeks, followed by 40",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day on three days a week for four weeks. Prednisolone was then discontinued. Seventeen children in the long taper group received 60",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day for four weeks, 60",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day on alternate days for four weeks, followed by tapering by 10",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      every other day every four weeks over five months. The number of patients who relapsed with the nephrotic syndrome within six months after initial taper was significantly higher in the rapid taper group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RECOMMENDED TAPERING REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term glucocorticoid therapy (up to three weeks), even if at a fairly high dose, can simply be stopped and need not be tapered. HPA suppression due to glucocorticoid use of this duration will not persist and is highly unlikely to have any clinical consequence. However, in a frail or dangerously ill patient, the clinician may elect to proceed more cautiously as noted below.",
"   </p>",
"   <p>",
"    In patients who have taken a glucocorticoid for a longer time, we suggest a regimen which is largely based upon experience and rests upon the following assumptions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factors of age, frailty, concomitant illnesses, dangerousness and likelihood of flare of underlying illness, psychological factors, and duration of previous use of glucocorticoids are taken into account.",
"     </li>",
"     <li>",
"      The disease is sufficiently stable so that tapering of the dose is appropriate.",
"     </li>",
"     <li>",
"      The patient has received long-term steroid therapy, not recurrent \"pulses\" as might be used in asthma.",
"     </li>",
"     <li>",
"      The observation that HPA suppression is uncommon at",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      doses below 5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The regimen we recommend also assumes that repeated morning cortisol determinations are too expensive for routine use (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Other published tapering regimens'",
"    </a>",
"    below) and that the appropriate end-points are the patient's signs and symptoms.",
"   </p>",
"   <p>",
"    The goal of tapering is to use a rate of change that will prevent both recurrent activity of the underlying disease and symptoms of cortisol deficiency due to persistent HPA suppression. We generally aim for a relatively stable decrement of 10 to 20 percent, while accommodating convenience and individual patient response. The dose is tapered by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      5 to 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every one to two weeks from an initial dose above 40 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent per day.",
"     </li>",
"     <li>",
"      5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every one to two weeks at",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      doses between 40 and 20",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      2.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every two to three weeks at",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      doses between 20 and 10",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      1",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every two to four weeks at",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      doses between 10 and 5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      0.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      every two to four weeks at",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      doses from 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      down. This can be achieved by alternating daily doses, eg, 5 mg on day 1 and 4 mg on day 2.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This regimen will generally prevent symptoms of cortisol deficiency. At some point, however, many patients with rheumatic diseases complain of recurrent symptoms of the underlying disease. In this setting it may be difficult to distinguish between mild symptoms of glucocorticoid withdrawal (ie, arthralgia and myalgia or \"pseudorheumatism\") or recrudescence of the underlying rheumatic disease.",
"   </p>",
"   <p>",
"    If the symptoms are not major, we try to wait 7 to 10 days, and use a nonsteroidal antiinflammatory drug or other analgesic. Resolution of symptoms during this period of time suggests pseudorheumatism. If the symptoms do not subside within this time frame, we increase the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose by 10 to 15 percent (to the next convenient mg tablet regimen) and maintain that dose for two to four weeks. If the symptoms resolve, the above tapering regimen can be resumed, using two to four weeks between decrements rather than one to two weeks.",
"   </p>",
"   <p>",
"    Should this modest increase in dose not be sufficient to alleviate symptoms, we double the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose. The disease flare is allowed to subside and the taper is reinstituted at a slower rate (eg, once monthly) or at smaller decrements (eg, one-half of the original decrement).",
"   </p>",
"   <p>",
"    It should also be appreciated that incremental change is inappropriate if life-threatening flares occur (as in acute recurrence of lupus nephritis, severe hemolysis, acute polymyositis, or vasculitis). In these settings, a return to the original, highest dose of steroids should be instituted. Tapering which is slowed in rate or decrement can be undertaken after the flare subsides, but specific guidelines become both convoluted and impractical in the latter situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Alternate-day regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are not aware of any evidence-based data relating to steroid tapering on an alternate-day regimen. We do, however, use the following alternate-day approach (in which the entire dose is given on the alternate days) in some patients. After the daily regimen has reached 20 to 30 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day, we decrease the alternate day dose by 5 mg every one to two weeks until the dose is 20 to 30 mg alternating with 10 mg. We then reduce the alternate day dose by 2.5 mg every one to two weeks until the prednisone dose on the alternate day has fallen to zero. At that point we decrease the remaining drug in the same manner as was suggested for the daily dosing regimen.",
"   </p>",
"   <p>",
"    Although this regimen is generally effective in most rheumatic diseases, patients with rheumatoid arthritis often do not tolerate alternate-day dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OTHER PUBLISHED TAPERING REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other published glucocorticoid tapering regimens include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report in 1976 used plasma cortisol measurements to gauge withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/17\">",
"       17",
"      </a>",
"      ]. Patients returned to the clinic at two to four week intervals for morning plasma cortisol measurement. Tapering was done at a rate of 2.5 mg of",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"        hydrocortisone",
"       </a>",
"       /week",
"      </span>",
"      down to a single morning dose of 10 mg of hydrocortisone (equivalent to 2 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ). Steroid therapy could be discontinued when the morning plasma cortisol concentration rose to greater than 10",
"      <span class=\"nowrap\">",
"       mcg/dL.",
"      </span>",
"      Stress doses of steroids might be needed for infections. This approach, however, has not gained much popularity and is generally not used.",
"     </li>",
"     <li>",
"      Another report in patients with rheumatic disease suggested either switching to alternate-day therapy or gradually lowering the daily dose [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22103/abstract/18\">",
"       18",
"      </a>",
"      ]. To switch to an alternate-day regimen, the dose was doubled on alternate days and then tapered as described below. This regimen, however, might result in synovial and serosal flare and symptoms on the alternate days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21958300\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The indications for glucocorticoid withdrawal include achieving the maximum desired therapeutic benefit or inadequate benefit despite an adequate trial, and the development of serious or uncontrollable side effects from the medication. Immediate cessation or reduction to a physiologic dose as soon as possible is required in patients with steroid-induced acute psychosis and those with herpesvirus-induced corneal ulceration. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for withdrawing glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administration of exogenous glucocorticoids can suppress the hypothalamic-pituitary-adrenal axis (HPA). Abrupt cessation or too rapid withdrawal of glucocorticoids in such patients may cause symptoms of adrenal insufficiency. The potency, dose, and duration of glucocorticoid use are important but imperfect predictors of the presence of HPA suppression. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hypothalamic-pituitary-adrenal axis suppression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Identifying patients with HPA suppression'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=see_link&amp;anchor=H18#H18\">",
"       \"Pharmacologic use of glucocorticoids\", section on 'HPA axis suppression'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The response to administration of synthetic adrenocorticotropic hormone (ACTH [cosyntropin]) is the preferred method to assess adrenocortical function. Testing for HPA-axis function is appropriate when patients are using &le; 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and there is difficulty reducing the dose further because of non-disease related symptoms. In most patients who require testing, we use the low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"       ACTH stimulation test",
"      </a>",
"      for initial testing. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Estimation of HPA suppression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Low-dose ACTH stimulation test'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Recommendation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CRH stimulation testing may be used in patients with normal adrenal responsiveness based upon ACTH stimulation testing, but continued non-disease related symptoms with further attempts to reduce glucocorticoid dosing. CRH testing can assess both the ACTH and cortisol responses if there is concern about pituitary function. It is rarely required. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Estimation of HPA suppression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Corticotropin releasing hormone (CRH) test'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Recommendation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Forms of steroid dependence other than symptomatic and biochemical evidence of HPA suppression that can hinder steroid tapering include psychologic dependence on steroids, disease recrudescence, and symptoms of apparent adrenal insufficiency despite normal HPA function and lack of disease recrudescence. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Other forms of glucocorticoid dependence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a paucity of evidence to support any particular regimen of glucocorticoid tapering. Short-term glucocorticoid therapy (up to three weeks) can usually be stopped without a taper. In patients who have taken a glucocorticoid for a longer time, have a Cushingoid appearance, or received evening dosing, we suggest a regimen which is largely based upon experience and considers the patient&rsquo;s general health status, stability of the disease being treated, and the drug regimen that has been used. The usual end-points are the patient's signs and symptoms. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Tapering regimens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Recommended tapering regimen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Other published tapering regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of tapering is to use a rate of change that will prevent both recurrent activity of the underlying disease and symptoms of cortisol deficiency due to persistent HPA suppression. We generally aim for a relatively stable decrement of 5 to 10 percent every one to four weeks, while accommodating convenience and individual patient response. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Recommended tapering regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a paucity of data regarding alternate-day tapering regimens. These are generally effective in most rheumatic diseases, but patients with rheumatoid arthritis often do not tolerate alternate-day dosing. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Alternate-day regimen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kirwan JR. Systemic corticosteroids in rheumatology. In: Rheumatology, Hochberg MC, Silman AJ, Smolen JS (Eds), Mosby, St. Louis 2003. p.385.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/2\">",
"      Francisco GE, Honigberg IL, Stewart JT, et al. In vitro and in vivo bioequivalence of commercial prednisone tablets. Biopharm Drug Dispos 1984; 5:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/3\">",
"      Garg DC, Wagner JG, Sakmar E, et al. Rectal and oral absorption of methylprednisolone acetate. Clin Pharmacol Ther 1979; 26:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/4\">",
"      Rose JQ, Yurchak AM, Jusko WJ, Powell D. Bioavailability and disposition of prednisone and prednisolone from prednisone tablets. Biopharm Drug Dispos 1980; 1:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/5\">",
"      Legler UF, Benet LZ. Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives. Clin Pharmacol Ther 1986; 39:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/6\">",
"      Toothaker RD, Craig WA, Welling PG. Effect of dose size on the pharmacokinetics of oral hydrocortisone suspension. J Pharm Sci 1982; 71:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/7\">",
"      Pickup ME, Lowe JR, Leatham PA, et al. Dose dependent pharmacokinetics of prednisolone. Eur J Clin Pharmacol 1977; 12:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/8\">",
"      Hill MR, Szefler SJ, Ball BD, et al. Monitoring glucocorticoid therapy: a pharmacokinetic approach. Clin Pharmacol Ther 1990; 48:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/9\">",
"      Tornatore KM, Logue G, Venuto RC, Davis PJ. Pharmacokinetics of methylprednisolone in elderly and young healthy males. J Am Geriatr Soc 1994; 42:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/10\">",
"      Tornatore KM, Biocevich DM, Reed K, et al. Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. Transplantation 1995; 59:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/11\">",
"      Kimball CP. Psychological dependency on steroids? Ann Intern Med 1971; 75:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/12\">",
"      Dixon RB, Christy NP. On the various forms of corticosteroid withdrawal syndrome. Am J Med 1980; 68:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/13\">",
"      Richter B, Neises G, Clar C. Glucocorticoid withdrawal schemes in chronic medical disorders. A systematic review. Endocrinol Metab Clin North Am 2002; 31:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/14\">",
"      Brignola C, De Simone G, Belloli C, et al. Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther 1994; 8:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/15\">",
"      Hings IM, Filipovich AH, Miller WJ, et al. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation 1993; 56:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/16\">",
"      Ueda N, Chihara M, Kawaguchi S, et al. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. J Pediatr 1988; 112:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/17\">",
"      Byyny RL. Withdrawal from glucocorticoid therapy. N Engl J Med 1976; 295:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22103/abstract/18\">",
"      Nelson AM, Conn DL. Series on pharmacology in practice. 9. Glucocorticoids in rheumatic disease. Mayo Clin Proc 1980; 55:758.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7983 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-287B6DBA01-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22103=[""].join("\n");
var outline_f21_37_22103=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21958300\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR WITHDRAWING GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GLUCOCORTICOID PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Steroid pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HYPOTHALAMIC-PITUITARY-ADRENAL AXIS SUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Identifying patients with HPA suppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - HPA suppression likely",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - HPA suppression unlikely",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Intermediate/uncertain risk of HPA suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Estimation of HPA suppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Low-dose ACTH stimulation test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Corticotropin releasing hormone (CRH) test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER FORMS OF GLUCOCORTICOID DEPENDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TAPERING REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RECOMMENDED TAPERING REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Alternate-day regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OTHER PUBLISHED TAPERING REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21958300\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7983\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7983|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/61/42972\" title=\"table 1\">",
"      Relative potency glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/58/17326\" title=\"table 2\">",
"      Corticosteroid drug interact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/17/5403\" title=\"table 3\">",
"      Corticosteroid coverage surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26311?source=related_link\">",
"      Corticotropin-releasing hormone stimulation test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_37_22104="Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis";
var content_f21_37_22104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/37/22104/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22104/contributors\">",
"     Scott L Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/37/22104/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22104/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22104/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/37/22104/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22104/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/37/22104/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive alcohol consumption is associated with a range of hepatic manifestations, including alcoholic fatty liver disease (with or without steatohepatitis), acute alcoholic hepatitis, and cirrhosis. Patients with an alcohol intake of 30 or more grams per day are at increased risk of cirrhosis, although the majority of patients will not develop cirrhosis despite heavy alcohol intake (point prevalence of 1 percent for those who drink 30 to 60",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and 6 percent for those who drink 120",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few specific therapies available for patients with alcoholic liver disease. There is, however, one extremely important intervention, abstinence, since continued alcohol ingestion is the single most important risk factor for progression of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/2\">",
"     2",
"    </a>",
"    ]. Abstinence is also critical for those patients with cirrhosis to decrease the risk of complications. In addition, patients must be abstinent in order to be listed for liver transplantation. Referral to an alcohol rehabilitation program is usually necessary in combination with family support and counseling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5160?source=see_link\">",
"     \"Liver transplantation in alcoholic liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the prognosis and general management of alcoholic fatty liver disease and alcoholic cirrhosis. The clinical manifestations and diagnosis of alcoholic liver disease, the management of the complications of cirrhosis, the pathogenesis of alcoholic liver disease, and the approach to patients with acute alcoholic hepatitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=see_link\">",
"     \"Pathogenesis of alcoholic liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=see_link\">",
"     \"Alcoholic hepatitis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/43/698?source=see_link\">",
"     \"Alcoholic hepatitis: Natural history and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5160?source=see_link\">",
"     \"Liver transplantation in alcoholic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2010, the American Association for the Study of Liver Diseases and the American College of Gastroenterology issued a",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Documents/Bookmarked Practice Guidelines/AlcoholicLiverDisease1-2010.pdf\">",
"     joint guideline",
"    </a>",
"    for the management of patients with alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/3\">",
"     3",
"    </a>",
"    ]. Another",
"    <a class=\"external\" href=\"file://www.easl.eu/assets/application/files/5e1b5512fb2cabb_file.pdf\">",
"     guideline",
"    </a>",
"    was published in 2012 by the European Association for the Study of the Liver [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/4\">",
"     4",
"    </a>",
"    ]. The discussion that follows is generally consistent with these guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY AND PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol abuse may lead to steatosis, steatohepatitis, cirrhosis, and hepatocellular carcinoma. Not all patients who drink heavily develop alcoholic liver disease. However, once alcoholic liver disease develops, continued alcohol use typically leads to persistent and often progressive liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link&amp;anchor=H17187132#H17187132\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is estimated that 8 to 20 percent of patients with alcoholic fatty liver will progress to develop alcoholic cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/7\">",
"     7",
"    </a>",
"    ]. Factors associated with an increased risk of progression to cirrhosis include ongoing alcohol use, daily drinking rather than periodic binge drinking, cigarette smoking, obesity, female sex, and superimposed liver disease (eg, hepatitis B or C) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. On the other hand, drinking with meals appears to decrease the risk of progression. Factors associated with increased mortality include ongoing alcohol use, increasing age, higher Child-Pugh score, presence of complications of cirrhosis (encephalopathy, gastrointestinal bleeding), smoking, and coinfection with hepatitis B or C [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologic findings are also associated with patient outcomes. Hepatic inflammation (hepatitis) in patients with alcoholic liver disease increases the risk of progressing to cirrhosis and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/17\">",
"     17",
"    </a>",
"    ]. The presence of inflammatory cells (particularly neutrophils) on a liver biopsy is associated with a worse prognosis, independent of other histologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. In one series, liver biopsies were examined in 217 consecutive patients with alcoholic liver disease (140 with cirrhosis) who were observed for five years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with cirrhosis who had hepatitis (defined by the degree of inflammation and necrosis, as well as the presence of Mallory bodies) had significantly higher mortality rates than those without hepatitis (27 versus 7 percent at one year and 47 versus 31 percent at five years). Several additional histologic features have been described that are associated with a worse prognosis, including the presence of perivenular fibrosis and a mixed pattern of macrovesicular and microvesicular fat [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among those who develop cirrhosis, complications are common at the time of diagnosis and are predictive of subsequent mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. In a population-based study of 466 patients with alcoholic cirrhosis, mortality rates at one and five years depended on the complications present at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No complications (24 percent of patients): one- and five-year mortality rates of 17 and 58 percent, respectively",
"     </li>",
"     <li>",
"      Ascites alone (55 percent of patients): one- and five-year mortality rates of 20 and 59 percent, respectively",
"     </li>",
"     <li>",
"      Variceal bleeding alone (6 percent of patients): one- and five-year mortality rates of 29 and 65 percent, respectively",
"     </li>",
"     <li>",
"      Ascites and variceal bleeding (4 percent of patients): one- and five-year mortality rates of 49 and 80 percent, respectively",
"     </li>",
"     <li>",
"      Hepatic encephalopathy (with or without other complications; 11 percent of patients): one- and five-year mortality rates of 64 and 85 percent, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62577383\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of alcoholic liver disease centers on alcohol abstinence. In patients who have not yet progressed to cirrhosis, abstinence may allow for reversal of the hepatic changes induced by alcohol. In patients with cirrhosis, alcohol abstinence decreases the risk of hepatic decompensation and improves survival. Patients should be referred for treatment for alcohol abuse or dependence to increase the likelihood of successful abstinence. (See",
"    <a class=\"local\" href=\"#H253571802\">",
"     'Abstinence'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with alcoholic cirrhosis also require nutritional therapy and measures to prevent superimposed hepatic injury (eg, vaccination for hepatitis A and B). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Nutritional therapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=see_link\">",
"     \"Immunizations for patients with chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with decompensated cirrhosis are managed the same as patients with other forms of end-stage liver disease and require treatment for complications such as ascites, variceal bleeding, and hepatic encephalopathy. In some cases, liver transplantation may be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5160?source=see_link\">",
"     \"Liver transplantation in alcoholic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with acute alcoholic hepatitis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/43/698?source=see_link&amp;anchor=H234081667#H234081667\">",
"     \"Alcoholic hepatitis: Natural history and management\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H253571802\">",
"    <span class=\"h2\">",
"     Abstinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol abstinence has been associated with improved outcomes in patients with alcoholic liver disease, including histologic improvement, decreased rates of progression to cirrhosis, reductions in portal pressure, decreased rebleeding from varices, and improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/6,13,16,24-28\">",
"     6,13,16,24-28",
"    </a>",
"    ]. Abstinence is more likely among patients who receive treatment for alcohol abuse or dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies have shown that patients with alcoholic fatty liver who stop drinking may have resolution of their steatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. This was examined in a study that included 26 patients with alcoholic liver disease who had focal fatty lesions seen on computed tomographic (CT) scan [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/30\">",
"     30",
"    </a>",
"    ]. After abstaining from alcohol, all patients had changes in or resolution of the foci of fatty infiltration by six weeks (two patients had complete resolution within one week). In a second study, two patients who had steatosis demonstrated on liver biopsy in the setting of alcohol use were free of steatosis on biopsy one month after alcohol cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with fatty liver who continue to drink, patients who drink less alcohol have a better prognosis than those who drink more. A study of 88 patients with alcoholic fatty liver compared patients who drank &ge;400 grams of alcohol per week (approximately 29 standard drinks (",
"    <a class=\"graphic graphic_figure graphicRef56818 \" href=\"UTD.htm?20/18/20778\">",
"     figure 1",
"    </a>",
"    )) with those who drank less [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/21\">",
"     21",
"    </a>",
"    ]. Among the 37 patients who consumed &lt;400 grams of alcohol per week, none developed cirrhosis, and three (8 percent) developed fibrosis. Of the 51 patients who consumed &ge;400 grams of alcohol per week, nine (18 percent) developed cirrhosis, and seven (14 percent) developed lesser degrees of fibrosis. However, a major limitation of the study is that the 49 patients who did not have histologic follow-up were assumed to be free from cirrhosis or fibrosis.",
"   </p>",
"   <p>",
"    Abstinence can also be beneficial in patients with fibrosis or cirrhosis. Improvement in fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/18,19,33\">",
"     18,19,33",
"    </a>",
"    ], a reduction in or normalization of the portal pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/34\">",
"     34",
"    </a>",
"    ], and resolution (or reduction) of ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/35\">",
"     35",
"    </a>",
"    ] have accompanied alcohol abstinence in some patients. Several studies have demonstrated increased survival among patients with alcoholic cirrhosis who abstain from alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/6,13,16,26,28,36\">",
"     6,13,16,26,28,36",
"    </a>",
"    ]. As an example, in a study with 165 patients with alcoholic cirrhosis, 99 patients abstained from alcohol during follow-up, and 66 continued to drink [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/16\">",
"     16",
"    </a>",
"    ]. The patients were followed for a median of 54 months. Patients who abstained from alcohol had higher survival rates at 1, 5, and 10 years of follow-up (95 versus 63 percent, 61 versus 36 percent, and 31 versus 11 percent, respectively). Similarly, in a study that included 84 patients with alcoholic cirrhosis, survival rates after a median of 7 years were higher for those who abstained from alcohol compared with those who continued to drink (72 versus 44 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Nutritional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcoholism is associated with nutritional deficiencies including protein calorie malnutrition and deficiencies of vitamins and trace minerals, including vitamin A, vitamin D, thiamine, folate, pyridoxine, and zinc [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/37\">",
"     37",
"    </a>",
"    ]. In patients with alcoholic cirrhosis, protein calorie malnutrition increases the risk of major complications, such as infection, encephalopathy, and ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6889?source=see_link&amp;anchor=H2#H2\">",
"     \"Nutritional assessment in chronic liver disease\", section on 'Pathogenesis of malnutrition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/8/17544?source=see_link&amp;anchor=H430163140#H430163140\">",
"     \"Nutritional status in alcohol dependence\", section on 'Pathogenesis of malnutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients with alcoholic liver disease should undergo a nutritional assessment. Nutritional therapy is indicated for patients with alcoholic fatty liver who are malnourished or who have evidence of vitamin or mineral deficiencies. Patients with alcoholic fatty liver who are not malnourished and do not have evidence of vitamin or mineral deficiencies should be encouraged to eat a healthy, balanced diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6889?source=see_link\">",
"     \"Nutritional assessment in chronic liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/8/17544?source=see_link\">",
"     \"Nutritional status in alcohol dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link\">",
"     \"Healthy diet in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with alcoholic cirrhosis, general nutritional therapy is indicated because protein, carbohydrate, and lipid metabolism are all affected by liver disease. We agree with the recommendations of the American Association for the Study of Liver Diseases and American College of Gastroenterology that patients with alcoholic cirrhosis should eat multiple times per day, including breakfast and a nighttime snack. The diet should consist of higher amounts of protein (1.2 to 1.5",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    and total calories (35 to 40",
"    <span class=\"nowrap\">",
"     kcal/kg)",
"    </span>",
"    than are recommended in a standard healthy diet [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition to these general recommendations, patients should also be treated for any vitamin or mineral deficiencies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6889?source=see_link&amp;anchor=H74885369#H74885369\">",
"     \"Nutritional assessment in chronic liver disease\", section on 'Cirrhosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have attempted to determine if aggressive nutritional therapy improves outcomes in patients with alcoholic cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/39\">",
"     39",
"    </a>",
"    ]. While nutritional therapy has not been shown to improve mortality in most randomized trials, a systematic review that included 13 studies with 319 patients with alcoholic cirrhosis suggests that it improves nitrogen balance and albumin levels, decreases hospitalization rates, and decreases the frequency of complications related to cirrhosis (encephalopathy, gastrointestinal bleeding, ascites).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71655800\">",
"    <span class=\"h2\">",
"     Alcoholic hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the management of patients with alcoholic hepatitis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/43/698?source=see_link\">",
"     \"Alcoholic hepatitis: Natural history and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62577480\">",
"    <span class=\"h2\">",
"     Complications of cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with alcoholic cirrhosis who develop complications such as ascites, variceal bleeding, or hepatic encephalopathy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62577449\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have decompensated liver disease despite alcohol abstinence should be referred to a liver transplantation center for evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5160?source=see_link\">",
"     \"Liver transplantation in alcoholic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62577331\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple medications have been tested as possible treatments for alcoholic fatty liver disease. Many showed initial promise but were later found to be ineffective, and others continue to be studied. Three of the most studied medications are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    , s-adenosylmethionine (SAMe), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    . All appeared to be beneficial in initial studies, but none was subsequently found to be effective when systematic reviews and meta-analyses were conducted.",
"   </p>",
"   <p>",
"    Metadoxine is an antioxidant that has been approved for the treatment of alcoholic liver disease in Europe that may be effective. Complimentary medicines have also been studied, particularly silymarin (the active ingredient in milk thistle), but do not appear to have an effect on overall mortality, though silymarin may improve liver-related mortality in patients with alcoholic liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112726943\">",
"    <span class=\"h2\">",
"     Metadoxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metadoxine is a combination of two antioxidants, pyridoxine and pyrrolidone, and has been studied for the treatment of alcoholic liver disease because oxidative stress is one of the mechanisms of alcohol-induced liver damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of alcoholic liver disease\", section on 'Oxidative stress'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies in humans have demonstrated that metadoxine is associated with improvement in biochemical parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/40-44\">",
"     40-44",
"    </a>",
"    ], but further studies examining the long-term effects of metadoxine, as well as the effects of metadoxine on histologic findings such as steatosis, steatohepatitis, and fibrosis, are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112727283\">",
"    <span class=\"h2\">",
"     Propylthiouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcoholic liver disease is associated with a hypermetabolic state leading to increased oxygen consumption and pericentral hypoxia. These observations lead to studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    , which may attenuate the hypermetabolic response and reduce pericentral hypoxia and cell injury. However, a meta-analysis of six randomized trials with 710 patients with alcoholic liver disease treated with propylthiouracil or placebo did not reveal a benefit with propylthiouracil with regard to histologic findings, overall mortality, or liver-related mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112727291\">",
"    <span class=\"h2\">",
"     S-adenosylmethionine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated the efficacy of s-adenosylmethionine (SAMe), a glutathione precursor, in the treatment of alcoholic liver disease. Glutathione is an antioxidant that protects the liver from oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/46\">",
"     46",
"    </a>",
"    ]. Although a potential reduction on mortality had been suggested in some reports [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/47\">",
"     47",
"    </a>",
"    ], a systematic review that included eight randomized trials found no significant benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of alcoholic liver disease\", section on 'Oxidative stress'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112727299\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale behind using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    for alcoholic liver disease is based on its many effects on fibrogenesis, including the inhibition of collagen production, enhancement of collagenase activity, and the interference with collagen transcellular trafficking [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. In addition, colchicine has favorable effects on cytokine production associated with fibroblast proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An initial randomized trial suggested a survival benefit in patients with cirrhosis who received oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/53\">",
"     53",
"    </a>",
"    ]. However, subsequent trials showed mixed results, and a meta-analysis of 15 randomized trials with 1714 patients with varying degrees of alcoholic liver disease found no benefit with colchicine on liver biochemical tests, liver histology, overall mortality, or liver-related mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112727407\">",
"    <span class=\"h2\">",
"     Complementary medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silymarin, the active ingredient in milk thistle, is thought to have antioxidant properties and has been proposed as a treatment for alcoholic liver disease. A meta-analysis of 13 trials with 915 patients with liver disease due to alcohol, hepatitis B,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatitis C found that milk thistle was not associated with a decrease in overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22104/abstract/55\">",
"     55",
"    </a>",
"    ]. However, it was associated with decreased liver-related mortality in the four studies that reported on that outcome, including the subgroup of 268 patients with alcoholic liver disease (RR 0.39, 95% CI 0.18-0.86). When the analysis was restricted to three high-quality trials, there was a trend toward a decrease in liver-related mortality among patients with liver disease, but the result was no longer statistically significant (relative risk [RR] 0.57, 95% confidence interval [CI] 0.28-1.19).",
"   </p>",
"   <p>",
"    Additional high-quality trials in patients with alcoholic liver disease are needed to confirm the findings of the subgroup analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alcohol abuse may lead to steatosis, steatohepatitis, cirrhosis, and hepatocellular carcinoma. Not all patients who drink heavily develop alcoholic liver disease. However, once alcoholic liver disease develops, continued alcohol use typically leads to persistent and often progressive liver disease. It is estimated that 8 to 20 percent of patients with alcoholic fatty liver will progress to develop alcoholic cirrhosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Natural history and prognostic factors'",
"      </a>",
"      above.) We recommend that patients with alcoholic fatty liver disease or alcoholic cirrhosis abstain from alcohol (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In patients who have not yet progressed to cirrhosis, abstinence may allow for reversal of the hepatic changes induced by alcohol. In patients with cirrhosis, alcohol abstinence decreases the risk of hepatic decompensation and improves survival. Treatment for alcohol use disorders is essential to reduce the likelihood of continued abuse and liver damage. (See",
"      <a class=\"local\" href=\"#H253571802\">",
"       'Abstinence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alcoholism is associated with nutritional deficiencies including protein calorie malnutrition and deficiencies of vitamins and trace minerals, so patients with alcoholic liver disease should undergo a nutritional assessment. Nutritional therapy is indicated for patients with alcoholic fatty liver who have evidence of malnutrition or vitamin or mineral deficiencies. We also suggest general nutritional therapy for all patients with cirrhosis, rather than a standard diet (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). General support in this setting consists of eating multiple times per day, including breakfast and a nighttime snack. The diet should consist of higher amounts of protein (1.2 to 1.5",
"      <span class=\"nowrap\">",
"       g/kg)",
"      </span>",
"      and total calories (35 to 40",
"      <span class=\"nowrap\">",
"       kcal/kg)",
"      </span>",
"      than are recommended in a standard healthy diet. While nutritional therapy has not been shown to improve mortality in most randomized trials of patients with alcoholic cirrhosis, it does appear to improve nitrogen balance and albumin levels, decrease hospitalization rates, and decrease the frequency of complications of cirrhosis (encephalopathy, gastrointestinal bleeding, ascites). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Nutritional therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have decompensated liver disease despite alcohol abstinence should be referred to a liver transplantation center for evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5160?source=see_link\">",
"       \"Liver transplantation in alcoholic liver disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medications continue to be studied for the treatment of alcoholic fatty liver and alcoholic cirrhosis. Some have shown promise, but additional high-quality trials are needed. (See",
"      <a class=\"local\" href=\"#H62577331\">",
"       'Experimental therapies'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/1\">",
"      Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/2\">",
"      Chedid A, Mendenhall CL, Gartside P, et al. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol 1991; 86:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/3\">",
"      O'Shea RS, Dasarathy S, McCullough AJ, et al. Alcoholic liver disease. Hepatology 2010; 51:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/4\">",
"      European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/5\">",
"      Par&eacute;s A, Caballer&iacute;a J, Bruguera M, et al. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986; 2:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/6\">",
"      Borowsky SA, Strome S, Lott E. Continued heavy drinking and survival in alcoholic cirrhotics. Gastroenterology 1981; 80:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/7\">",
"      Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/8\">",
"      Saunders JB, Davis M, Williams R. Do women develop alcoholic liver disease more readily than men? Br Med J (Clin Res Ed) 1981; 282:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/9\">",
"      Barrio E, Tom&eacute; S, Rodr&iacute;guez I, et al. Liver disease in heavy drinkers with and without alcohol withdrawal syndrome. Alcohol Clin Exp Res 2004; 28:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/10\">",
"      Hatton J, Burton A, Nash H, et al. Drinking patterns, dependency and life-time drinking history in alcohol-related liver disease. Addiction 2009; 104:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/11\">",
"      Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/12\">",
"      Raynard B, Balian A, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002; 35:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/13\">",
"      Pessione F, Ramond MJ, Peters L, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/14\">",
"      Jepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010; 51:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/15\">",
"      Orrego H, Israel Y, Blake JE, Medline A. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology 1983; 3:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/16\">",
"      Alvarez MA, Cirera I, Sol&agrave; R, et al. Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients. J Clin Gastroenterol 2011; 45:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/17\">",
"      Orrego H, Blake JE, Blendis LM, Medline A. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987; 92:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/18\">",
"      Alexander JF, Lischner MW, Galambos JT. Natural history of alcoholic hepatitis. II. The long-term prognosis. Am J Gastroenterol 1971; 56:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/19\">",
"      Powell WJ Jr, Klatskin G. Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968; 44:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/20\">",
"      Galambos JT. Alcoholic hepatitis: its therapy and prognosis. Prog Liver Dis 1972; 4:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/21\">",
"      Teli MR, Day CP, Burt AD, et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/22\">",
"      Worner TM, Lieber CS. Perivenular fibrosis as precursor lesion of cirrhosis. JAMA 1985; 254:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/23\">",
"      Nakano M, Worner TM, Lieber CS. Perivenular fibrosis in alcoholic liver injury: ultrastructure and histologic progression. Gastroenterology 1982; 83:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/24\">",
"      Brunt PW, Kew MC, Scheuer PJ, Sherlock S. Studies in alcoholic liver disease in Britain. I. Clinical and pathological patterns related to natural history. Gut 1974; 15:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/25\">",
"      Luca A, Garc&iacute;a-Pag&aacute;n JC, Bosch J, et al. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997; 112:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/26\">",
"      Muntaner L, Altamirano JT, Augustin S, et al. High doses of beta-blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding. Liver Int 2010; 30:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/27\">",
"      Veldt BJ, Lain&eacute; F, Guillygomarc'h A, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002; 36:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/28\">",
"      Senanayake SM, Niriella MA, Weerasinghe SK, et al. Survival of patients with alcoholic and cryptogenic cirrhosis without liver transplantation: a single center retrospective study. BMC Res Notes 2012; 5:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/29\">",
"      Friedmann PD. Clinical practice. Alcohol use in adults. N Engl J Med 2013; 368:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/30\">",
"      Tang-Barton P, Vas W, Weissman J, et al. Focal fatty liver lesions in alcoholic liver disease: a broadened spectrum of CT appearances. Gastrointest Radiol 1985; 10:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/31\">",
"      Bashist B, Hecht HL, Harley WD. Computed tomographic demonstration of rapid changes in fatty infiltration of the liver. Radiology 1982; 142:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/32\">",
"      Lieber CS, Rubin E. Alcoholic fatty liver in man on a high protein and low fat diet. Am J Med 1968; 44:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/33\">",
"      Niemel&auml; O, Risteli J, Blake JE, et al. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 1990; 98:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/34\">",
"      REYNOLDS TB, GELLER HM, KUZMA OT, REDEKER AG. Spontaneous decrease in portal pressure with clinical improvement in cirrhosis. N Engl J Med 1960; 263:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/35\">",
"      Runyon BA. Historical aspects of treatment of patients with cirrhosis and ascites. Semin Liver Dis 1997; 17:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/36\">",
"      Verrill C, Markham H, Templeton A, et al. Alcohol-related cirrhosis--early abstinence is a key factor in prognosis, even in the most severe cases. Addiction 2009; 104:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/37\">",
"      Mezey E. Interaction between alcohol and nutrition in the pathogenesis of alcoholic liver disease. Semin Liver Dis 1991; 11:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/38\">",
"      Mendenhall CL, Anderson S, Weesner RE, et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984; 76:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/39\">",
"      Stickel F, Hoehn B, Schuppan D, Seitz HK. Review article: Nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 2003; 18:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/40\">",
"      Caballer&iacute;a J, Par&eacute;s A, Br&uacute; C, et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol 1998; 28:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/41\">",
"      Rizzo A, Breda A, Moretto F, et al. [Therapeutic use of metadoxine in chronic alcoholism. Double blind study of patients in a department of general medicine]. Clin Ter 1993; 142:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/42\">",
"      Corsini G, Gelso E, Giuliano G. [Effects of metadoxine on main biohumoral changes induced by chronic alcoholism]. Clin Ter 1992; 140:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/43\">",
"      Santoni S, Corradini P, Zocchi M, Camarri F. [Metadoxine in alcohol-related pathology]. Clin Ter 1989; 130:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/44\">",
"      Mao YM, Zeng MD, Li YM, et al. [Capsule metadoxine in the treatment of alcoholic liver disease: a randomized, double-blind, placebo-controlled, multicenter study]. Zhonghua Gan Zang Bing Za Zhi 2009; 17:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/45\">",
"      Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev 2002; :CD002800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/46\">",
"      Ishii H, Kurose I, Kato S. Pathogenesis of alcoholic liver disease with particular emphasis on oxidative stress. J Gastroenterol Hepatol 1997; 12:S272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/47\">",
"      Mato JM, C&aacute;mara J, Fern&aacute;ndez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/48\">",
"      Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2001; :CD002235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/49\">",
"      Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 2008; 12:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/50\">",
"      Entzian P, Schlaak M, Seitzer U, et al. Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung 1997; 175:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/51\">",
"      Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep 2002; 4:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/52\">",
"      Kershenobich D, Rojkind M, Quiroga A, Alcocer-Varela J. Effect of colchicine on lymphocyte and monocyte function and its relation to fibroblast proliferation in primary biliary cirrhosis. Hepatology 1990; 11:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/53\">",
"      Kershenobich D, Vargas F, Garcia-Tsao G, et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988; 318:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/54\">",
"      Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2005; :CD002148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22104/abstract/55\">",
"      Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases--a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005; 100:2583.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3611 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22104=[""].join("\n");
var outline_f21_37_22104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NATURAL HISTORY AND PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62577383\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H253571802\">",
"      Abstinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Nutritional therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71655800\">",
"      Alcoholic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62577480\">",
"      Complications of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62577449\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62577331\">",
"      EXPERIMENTAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112726943\">",
"      Metadoxine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112727283\">",
"      Propylthiouracil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112727291\">",
"      S-adenosylmethionine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112727299\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112727407\">",
"      Complementary medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3611\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3611|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/18/20778\" title=\"figure 1\">",
"      Standard alcoholic drink PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=related_link\">",
"      Alcoholic hepatitis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/43/698?source=related_link\">",
"      Alcoholic hepatitis: Natural history and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=related_link\">",
"      Immunizations for patients with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5160?source=related_link\">",
"      Liver transplantation in alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6889?source=related_link\">",
"      Nutritional assessment in chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/8/17544?source=related_link\">",
"      Nutritional status in alcohol dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30807?source=related_link\">",
"      Pathogenesis of alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_37_22105="HS Crohns1";
var content_f21_37_22105=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81233%7EOBGYN%2F58354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81233%7EOBGYN%2F58354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crohn's disease mimicking hidradenitis suppurativa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crohn's disease mimicking hidradenitis suppurativa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22105=[""].join("\n");
var outline_f21_37_22105=null;
var title_f21_37_22106="Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications";
var content_f21_37_22106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/37/22106/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22106/contributors\">",
"     Eric Bow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/37/22106/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22106/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/37/22106/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/37/22106/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/37/22106/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1169494774\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients receiving cytotoxic antineoplastic therapy sufficient to adversely affect myelopoiesis and the developmental integrity of the gastrointestinal mucosa are at risk for invasive infection due to colonizing bacteria or fungi that translocate across intestinal mucosal surfaces. Since the magnitude of the neutrophil-mediated component of the inflammatory response may be muted in neutropenic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/1\">",
"     1",
"    </a>",
"    ], an elevated body temperature may be the earliest and only sign of infection. It is critical to recognize neutropenic fever early and to initiate empiric systemic antibacterial therapy promptly in order to avoid progression to a sepsis syndrome and possibly death.",
"   </p>",
"   <p>",
"    The treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications will be reviewed here. The treatment and prevention of neutropenic fever in adults at high risk for complications are discussed separately. An overview of neutropenic fever syndromes, the risk assessment of patients with neutropenic fever, the diagnostic approach to patients presenting with neutropenic fever, and the use of colony stimulating factors in patients with chemotherapy-induced neutropenia are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"     \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neutropenic fever in children is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link\">",
"     \"Fever in children with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105832552\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines have been developed for the prevention and management of fever in neutropenic patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. The recommendations below are generally in keeping with the 2010 Infectious Diseases Society of America (IDSA) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2\">",
"     2",
"    </a>",
"    ] and the 2013 American Society of Clinical Oncology (ASCO) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that our approach differs slightly from the approach of IDSA and ASCO because we consider low-risk patients to be those who are anticipated to have an ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (rather than &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    for &le;7 days. The rationale for choosing this threshold is discussed below. (See",
"    <a class=\"local\" href=\"#H9532986\">",
"     'Risk of serious complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9532962\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9532970\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever in neutropenic patients is defined as a single oral temperature of &gt;38.3 &deg;C (101&deg;F) or a temperature of &gt;38.0&deg;C (100.4&deg;F) sustained for &gt;1 hour [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2\">",
"     2",
"    </a>",
"    ]. The definition of fever and appropriate methods for measuring body temperature are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H278237232#H278237232\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Fever'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H86779646#H86779646\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Temperature measurement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9532978\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of neutropenia varies from institution to institution but neutropenia is usually defined as an absolute neutrophil count (ANC) &lt;1500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    and severe neutropenia as an ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    or an ANC that is expected to decrease to &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    over the next 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. The risk of clinically important infection rises as the neutrophil count falls below 500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and is higher in those with a prolonged duration of neutropenia (&gt;7 days). For the purposes of this discussion,",
"    <strong>",
"     we will define neutropenia as an ANC &lt;500",
"     <span class=\"nowrap\">",
"      cells/microL.",
"     </span>",
"    </strong>",
"   </p>",
"   <p>",
"    The",
"    ANC can be calculated by multiplying the total white blood cell (WBC) count by the percentage of polymorphonuclear cells (PMNs) and bands (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H981551211#H981551211\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9532986\">",
"    <span class=\"h1\">",
"     RISK OF SERIOUS COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical evaluation focuses on assessing the risk of serious complications. This risk assessment dictates the approach to therapy, including the need for inpatient admission, IV antibiotics, and prolonged hospitalization (",
"    <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Low-risk patients are defined as those who are expected to be neutropenic (absolute neutrophil count [ANC] &lt;500",
"       <span class=\"nowrap\">",
"        cells/microL)",
"       </span>",
"       for &le;7 days and those with no comorbidities or evidence of significant hepatic or renal dysfunction.",
"      </strong>",
"      This group of patients has been well studied in randomized trials and has been shown to be at low risk for serious complications [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2\">",
"       2",
"      </a>",
"      ]. Most patients receiving chemotherapy for solid tumors are considered to be low-risk for complications requiring hospitalization or prolonging hospitalization.",
"     </li>",
"     <li>",
"      <strong>",
"       We define high-risk patients as those who are expected to be neutropenic (ANC &lt;500",
"       <span class=\"nowrap\">",
"        cells/microL)",
"       </span>",
"       for &gt;7 days. Patients with neutropenic fever who have ongoing comorbidities or evidence of significant hepatic or renal dysfunction are also considered to be high-risk, regardless of the duration of neutropenia.",
"      </strong>",
"      Other criteria that confer a high-risk status can be found in the Table (",
"      <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"       table 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Some experts have defined high-risk patients as those expected to have profound neutropenia (ANC &le;100",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      for &gt;7 days based on experience that such patients are the most likely to have life-threatening complications [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2,4,7\">",
"       2,4,7",
"      </a>",
"      ]. However, formal studies to clearly differentiate between patients with an ANC &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and &le;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      are lacking. For the purposes of this discourse, we will combine these groups. Profound prolonged neutropenia (ie, ANC &le;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      expected to last &gt;7 days) is most likely to occur in the pre-engraftment phase of hematopoietic cell transplantation (particularly allogeneic) and in patients undergoing induction chemotherapy for acute leukemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An alternative to using the clinical criteria described above is to use the Multinational Association for Supportive Care in Cancer (MASCC) risk index, which is a validated tool for measuring the risk for neutropenic fever-related medical complications (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?14/34/14881?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk assessment of patients with neutropenic fever is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169494934\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of infections in patients with neutropenic fever are due to the patient&rsquo;s endogenous flora. The Table lists the range of pathogens found in both high-risk and low-risk patients with chemotherapy-induced neutropenia (",
"    <a class=\"graphic graphic_table graphicRef63465 \" href=\"UTD.htm?0/44/718\">",
"     table 2",
"    </a>",
"    ). In one study that included 757 patients with neutropenic fever at low risk for medical complications, unexplained fevers accounted for 58 percent of the episodes, and microbiologically documented and clinically documented infections accounted for 21 percent of episodes each [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/10\">",
"     10",
"    </a>",
"    ]. Single gram-positive and gram-negative organisms were associated with 49 percent and 36 percent of the microbiologically documented infections, respectively. Polymicrobial infections, the majority of which (52 percent) contained both gram-positive and gram-negative bacteria, comprised the remaining 15 percent of episodes. Bacteremia, and in particular, gram-negative bacteremia, is more common when the absolute neutrophil count (ANC) is",
"    <span class=\"nowrap\">",
"     &lt;100/microL,",
"    </span>",
"    in highly symptomatic or moribund patients, in patients with hypotension, and in patients older than 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common bloodstream isolates in low-risk patients are gram-positive cocci in almost one-half (49 percent) of the cases, with the majority being due to coagulase-negative staphylococci or Staphylococcus aureus (",
"    <a class=\"graphic graphic_table graphicRef63465 \" href=\"UTD.htm?0/44/718\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/10\">",
"     10",
"    </a>",
"    ]. Just over one-third (36 percent) of bloodstream isolates are gram-negative bacilli, of which just over one-half (52 percent) are due to members of the family Enterobacteriaceae (Escherichia coli, Klebsiella spp, and Enterobacter spp) and the remainder are due to nonfermenting gram-negative bacilli, including P. aeruginosa, Stenotrophomonas maltophilia, Acinetobacter spp, and Haemophilus influenzae.",
"   </p>",
"   <p>",
"    Fungal infections are uncommon in low-risk patients with neutropenic fever. Reactivation of herpes simplex virus and varicella-zoster virus is also rare in low-risk patients. (See",
"    <a class=\"local\" href=\"#H247552649\">",
"     'Antifungal prophylaxis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H247552830\">",
"     'HSV and VZV'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The epidemiology of infections in patients with neutropenic fever is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H9533703#H9533703\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453916929\">",
"    <span class=\"h1\">",
"     INITIAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients presenting with neutropenic fever, a reliable method for obtaining body temperature must be used and a mechanism for estimating the absolute neutrophil count (ANC) is mandatory. The temperature should be taken using oral or tympanic thermometry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H86779646#H86779646\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Temperature measurement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453916950\">",
"    <span class=\"h2\">",
"     Risk of neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and their families should be instructed by their oncologist to inform healthcare providers in the triage setting about recent chemotherapy, and providers in the triage setting should ask cancer patients who do not offer this information about recent chemotherapy. The ANC can be estimated based upon the timing of the febrile episode following the first dose of the current cytotoxic chemotherapy or from a laboratory-based measurement of the ANC from a complete blood count (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). Knowledge that the ANC reaches its nadir of &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    a median of 12 to 14 days from day one of chemotherapy can guide the clinician to the correct index of suspicion regarding the likelihood of neutropenia.",
"   </p>",
"   <p>",
"    Over 70 percent of cancer recipients who develop systemic therapy-related complications present to emergency triage facilities within four to six weeks of systemic anti-cancer treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/12\">",
"     12",
"    </a>",
"    ]. The use of a sensitive but nonspecific historical indicator, receipt of systemic anti-cancer therapy within the preceding six weeks, has been advocated for use in emergency triage departments to identify patients who are likely to be neutropenic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453917003\">",
"    <span class=\"h2\">",
"     High-risk versus low-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, it is crucial to assess the risk for serious complications in patients with neutropenic fever, since this assessment will dictate the approach to therapy, including the need for inpatient admission, IV antibiotics, and prolonged hospitalization. (See",
"    <a class=\"local\" href=\"#H9532986\">",
"     'Risk of serious complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453917078\">",
"    <span class=\"h2\">",
"     Risk of sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the signs and symptoms of infection may be significantly muted in neutropenic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/1,14\">",
"     1,14",
"    </a>",
"    ], an early part of the clinical assessment at triage should include a determination of the criteria for systemic inflammatory response syndrome (SIRS), sepsis (SIRS plus evidence for a focus of infection), severe sepsis (sepsis plus evidence for new end-organ dysfunction such as altered mental status, hypoperfusion, hypoxia, or oliguria), or septic shock (severe sepsis plus hypotension refractory to adequate fluid resuscitation) (",
"    <a class=\"graphic graphic_algorithm graphicRef57616 \" href=\"UTD.htm?35/16/36100\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    All patients who have received systemic antineoplastic therapy within the previous six weeks and who present with SIRS should be presumed to have a neutropenic sepsis syndrome until proven otherwise [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/13\">",
"     13",
"    </a>",
"    ]. SIRS is defined by the presence of &ge;2 of the following conditions: temperature &gt;38&deg;C or &lt;36&deg;C; heart rate",
"    <span class=\"nowrap\">",
"     &gt;90/minute;",
"    </span>",
"    respirations",
"    <span class=\"nowrap\">",
"     &gt;20/minute;",
"    </span>",
"    PaCO2 &lt;32 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients presenting with evidence of new organ dysfunction (altered mental status, hypotension, hypoxia, or oliguria) should be managed emergently for severe sepsis. The following algorithm provides a suggested time-dependent care pathway for neutropenic cancer patients presenting at an emergency triage facility based upon historical and observational clinical criteria assessable at presentation (",
"    <a class=\"graphic graphic_algorithm graphicRef57616 \" href=\"UTD.htm?35/16/36100\">",
"     algorithm 1",
"    </a>",
"    ). Patients with evidence for septic shock should be managed in a critical care hospital environment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H453917156\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of patients presenting with neutropenic fever should be obtained promptly. The diagnostic approach is summarized in the following Table (",
"    <a class=\"graphic graphic_table graphicRef50509 \" href=\"UTD.htm?23/55/24444\">",
"     table 3",
"    </a>",
"    ), and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"     \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169494817\">",
"    <span class=\"h1\">",
"     EMPIRIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1636049913\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever in a neutropenic patient should be considered a medical emergency. Assessment by a physician should occur soon (eg, within 15 minutes) after triage for patients presenting with neutropenic fever within six weeks of having received chemotherapy for malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/7\">",
"     7",
"    </a>",
"    ]. Broad-spectrum antibacterials should be given as soon as possible and at full doses, adjusted for renal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatic function. In addition, the diagnostic evaluation should be obtained quickly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"     \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The aim of empiric therapy is to cover the spectrum of the most likely and most virulent pathogens that may rapidly cause serious or life-threatening infection in neutropenic patients (",
"    <a class=\"graphic graphic_table graphicRef63465 \" href=\"UTD.htm?0/44/718\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2\">",
"     2",
"    </a>",
"    ]. The following general principles apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotics are usually administered empirically, but should always include appropriate coverage for suspected or known infections. Even when the pathogen is known, the antibiotic regimen should provide broad-spectrum empiric coverage for the possibility of other pathogens, unlike the treatment strategy adopted in many immunocompetent hosts.",
"     </li>",
"     <li>",
"      Initial antibiotic selection should be guided by the patient's history, allergies, symptoms, signs, recent antibiotic use and culture data, and awareness of the susceptibility patterns of institutional nosocomial pathogens [",
"      <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ideally, antibiotics should be bactericidal and should be administered through alternate ports of central venous catheters, if present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical response and culture and susceptibility results should be monitored closely, and therapy should be adjusted in a timely fashion in response to this information [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376946545\">",
"    <span class=\"h3\">",
"     Timing of antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all febrile neutropenic patients, empiric broad-spectrum antibacterial therapy should be initiated immediately after blood cultures have been obtained and before any other investigations have been completed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. Antimicrobial therapy should be administered within",
"    <strong>",
"     60 minutes",
"    </strong>",
"    of presentation (",
"    <a class=\"graphic graphic_algorithm graphicRef57616 \" href=\"UTD.htm?35/16/36100\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/7,13,15,21\">",
"     7,13,15,21",
"    </a>",
"    ]. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H24660640#H24660640\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Timing of antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1636051077\">",
"    <span class=\"h3\">",
"     Spectrum of coverage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although gram-positive bacteria are the most frequent pathogens identified during neutropenic fever episodes, it is important to cover broadly for gram-negative pathogens because of their virulence and association with sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Furthermore, gram-negative organisms continue to cause the majority of infections in sites outside of the bloodstream (eg, respiratory tract, biliary tract, gastrointestinal tract, urinary tract, and skin) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/24\">",
"     24",
"    </a>",
"    ], and a rising number of infections are polymicrobial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/22,23,25\">",
"     22,23,25",
"    </a>",
"    ]. Clinicians need to be aware of the current microbiology surveillance data from their own institution, which can vary widely from center to center and over time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/19,22\">",
"     19,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169494839\">",
"    <span class=\"h2\">",
"     Initial regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial regimen and site of care (inpatient versus outpatient) depends on whether the patient is at high risk or low risk for medical complications (",
"    <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"     table 1",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H9532986\">",
"     'Risk of serious complications'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients who are considered to be high-risk require hospital admission for IV antibiotics, and often require a prolonged length of stay. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast, patients who clearly meet",
"      <strong>",
"       all",
"      </strong>",
"      criteria for being low-risk can be given oral antibiotics as outpatients, following either a brief period of observation or a short hospital admission. (See",
"      <a class=\"local\" href=\"#H247552555\">",
"       'Site of care'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommended initial empiric oral antibacterial regimen for low-risk patients involves a combination of a fluoroquinolone (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    750 mg orally twice daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    750 mg orally once daily) and a beta-lactam agent, such as amoxicillin-clavulanic acid (500",
"    <span class=\"nowrap\">",
"     mg/125",
"    </span>",
"    mg orally three times daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. In two trials of low-risk inpatients with neutropenic fever, oral ciprofloxacin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    had similar efficacy to IV regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In one of these trials, treatment was successful without the need for modifications in 71 percent of episodes in those who received an oral regimen, compared with 67 percent of episodes in those who received IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients receiving fluoroquinolone-based antibacterial prophylaxis should",
"    <strong>",
"     not",
"    </strong>",
"    receive a fluoroquinolone-based initial empiric antibacterial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. Such patients should receive one of the IV regimens recommended for high-risk patients in order to provide adequate activity against P. aeruginosa (",
"    <a class=\"graphic graphic_algorithm graphicRef60657 \" href=\"UTD.htm?40/56/41856\">",
"     algorithm 2",
"    </a>",
"    ); the fluoroquinolones are the only oral antibiotics with activity against P. aeruginosa. It is reasonable to give an IV antibiotic regimen on an outpatient basis provided that the patient meets all the criteria for being at low risk for complications. Empiric IV regimens for neutropenic fever are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H154974278#H154974278\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Initial regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who have a history of penicillin hypersensitivity,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (300 mg four times daily) may be given in place of amoxicillin-clavulanic acid or, if a cephalosporin is deemed to be safe,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    (400 mg once daily) may be given [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=see_link\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The safety and efficacy of outpatient oral antibiotics for low-risk patients with neutropenic fever have been best evaluated in trials comparing outpatient oral antibiotics with outpatient IV antibiotics. In a meta-analysis of eight trials that compared outpatient oral antibiotics with outpatient IV antibiotics for 857 neutropenic fever episodes, there was no association between route of antibiotic administration and treatment failure (RR 0.93, 95% CI 0.65-1.32) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/29\">",
"     29",
"    </a>",
"    ]. No deaths occurred in either group. It is important to note that in another meta-analysis, the rates of adverse events requiring regimen discontinuation were higher among low-risk patients receiving initial empiric antibacterial therapy with an oral regimen compared with an IV regimen (4.3 versus 0.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H247552555\">",
"    <span class=\"h2\">",
"     Site of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;As stated above, patients who meet",
"    <strong>",
"     all",
"    </strong>",
"    criteria for being at low risk for complications of neutropenic fever can be treated as outpatients, following either a brief period of observation or a short hospital admission (see",
"    <a class=\"local\" href=\"#H9532986\">",
"     'Risk of serious complications'",
"    </a>",
"    above). The initial therapy for neutropenic patients who are being considered for outpatient management and who have evidence of a systemic inflammatory response syndrome (SIRS) or a sepsis syndrome (SIRS plus a clinical focus of infection) should be administered under observation to ascertain tolerance and ensure timeliness of administration of the first dose. We favor monitoring patients for at least four hours after the initial dose of antibiotics before sending them home [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Most studies have observed patients in the hospital for the first 24 hours of empiric therapy, although in some studies patients were discharged as early as six hours after the initial dose of antibiotics was administered [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hospitalized low-risk patients who are initially given IV antibiotics and who are stable and have responded to therapy, especially those classified as having unexplained neutropenic fever, may be switched to an oral regimen and discharged [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/7\">",
"     7",
"    </a>",
"    ]. In such patients, plans should be made for outpatient follow-up and monitoring.",
"   </p>",
"   <p>",
"    The benefits of outpatient oral therapy include reduced cost [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/32\">",
"     32",
"    </a>",
"    ], lack of need for IV access, and improved patient acceptance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2,31\">",
"     2,31",
"    </a>",
"    ]. Not only outpatient oral therapy, but also outpatient IV therapy, is less costly than inpatient IV therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/33\">",
"     33",
"    </a>",
"    ]. In a survey of physician members of the American Society of Clinical Oncology, outpatient antibiotics were used by 82 percent of respondents for selected low-risk patients with neutropenic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of six trials that evaluated the efficacy and safety of inpatient therapy versus outpatient therapy for low-risk patients with neutropenic fever showed the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The site of care was not significantly associated with treatment failure.",
"     </li>",
"     <li>",
"      Death occurred in 13 of 742 neutropenic fever episodes (1.8 percent), with no difference between those who received inpatient versus outpatient therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent randomized trial evaluated the safety of early hospital discharge for low-risk patients with neutropenic fever, but was terminated early due to poor accrual; patients received IV antibiotics regardless of whether they were discharged [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/35\">",
"     35",
"    </a>",
"    ]. Major medical complications occurred in five episodes (8 percent) in the hospitalized group compared with four episodes (9 percent) in the outpatient group. Although these rates are comparable, this study was underpowered to show a difference in complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Readmission rates for outpatients managed with oral fluoroquinolone-based initial empiric antibacterial therapy have been reported to be in the range of 3 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80104940\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defervescence of fever and resolution of foci of infection present at baseline have been the primary outcomes sought by medical teams treating patients with neutropenic fever syndromes. The observed median times to defervescence for patients with neutropenic fever at high-risk and low-risk for medical complications have been five days and two days, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Febrile neutropenic patients should be monitored frequently in clinic or at home for at least the initial three days following presentation with neutropenic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/7\">",
"     7",
"    </a>",
"    ]. Features to monitor include vital signs (blood pressure, heart rate, respiratory rate, and temperature), performance status (the clinical burden of the neutropenic fever syndrome), and the ability to achieve adequate oral intake in the presence of oral or gastrointestinal mucositis. Attention to fluid and electrolyte management is important given the dehydrating effects of fever, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea. Temporarily holding administration of systemic chemotherapy should be considered during the management of the sepsis syndrome until the patient stabilizes.",
"   </p>",
"   <p>",
"    After the initial few days, patients should continue to be monitored with frequent (up to daily) telephone contact to verify resolution of fever. Patients should also have frequent clinic visits. The absolute neutrophil count and platelet count should be monitored to evaluate for myeloid reconstitution.",
"   </p>",
"   <p>",
"    Patients deemed eligible for outpatient management must be able to access medical care 24 hours daily, seven days per week, and should be able to reach the medical facility within one hour should the clinical condition worsen. Patients should be admitted to the hospital for IV antimicrobial therapy if they develop fever recrudescence, new signs or symptoms of infection, an inability to tolerate oral antibiotics, or if diagnostic tests identify species not susceptible to the initial empiric regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Persistence of fever beyond the expected median time to defervescence of two to three days should mandate a reassessment and consideration of modification of the initial empiric regimen and hospital admission. Persistent fever alone in a stable patient unaccompanied by any other signs or symptoms of progressive or new infection is not in itself a circumstance that warrants regimen modification [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. The need to modify the regimen should be driven by clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microbiologic evidence for resistant organisms and evidence of ongoing and progressive infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169494853\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antibacterial therapy for patients with clinically or microbiologically documented infections depends upon the clinical syndrome and pathogen. In general, antibacterial therapy is continued until myeloid reconstitution, defined by recovery of the absolute neutrophil count (ANC) to &ge;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The duration of treatment for unexplained fevers is largely a function of response to treatment, defined by defervescence, and myeloid reconstitution. In clinical trials, sustained defervescence has been defined as an afebrile period of four to five days among high-risk patients and 48 to 72 hours for low-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2\">",
"     2",
"    </a>",
"    ]. Accordingly, the duration of antibacterial therapy in low-risk patients with negative blood cultures has been based upon documentation of at least two afebrile days after the ANC has recovered. Among patients in whom the ANC has not recovered to &gt;500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    antibacterial therapy should be continued until the patient has been afebrile for five to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most documented infections, such as pneumonia or bloodstream infection, require 10 to 14 days of therapy, which may extend well beyond the time of myeloid reconstitution [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120313815\">",
"    <span class=\"h2\">",
"     Colony stimulating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colony stimulating factors (CSFs; also known as myeloid growth factors or hematopoietic growth factors), such as granulocyte and granulocyte-macrophage colony stimulating factors (G-CSF and GM-CSF), are generally",
"    <strong>",
"     not",
"    </strong>",
"    recommended for the management of patients with established fever and neutropenia, with some exceptions. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link&amp;anchor=H1163951#H1163951\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Neutropenic fever'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477726908\">",
"    <span class=\"h1\">",
"     MYELOID RECONSTITUTION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should be aware of the myeloid reconstitution syndrome, a circumstance in which there may be onset or progression of an inflammatory focus defined clinically or radiologically temporally related to neutrophil recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/40\">",
"     40",
"    </a>",
"    ]. Because such processes may appear in the context of a persistent neutropenic fever syndrome, the likelihood of superinfection must be considered with respect to the antimicrobial spectrum of the patient&rsquo;s current empiric antibacterial therapy and the microbiologic differential diagnosis applicable to those circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H247552339#H247552339\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Neutropenic fever syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344318\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of the treatment of patients with neutropenic fever syndromes has improved greatly as demonstrated by a progressive decline in mortality rates since the prompt initiation of empiric coverage was implemented in the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/24,41,42\">",
"     24,41,42",
"    </a>",
"    ]. Studies from the 1960s, before the routine use of empiric therapy, documented mortality rates of 90 percent in neutropenic patients with bacteremia caused by gram-negative bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In contrast, in a study of 41,779 adults with cancer who were hospitalized with neutropenic fever in the United States between 1995 and 2000, the in-hospital mortality was 9.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/45\">",
"     45",
"    </a>",
"    ]. The mortality rate depended upon the underlying malignancy: 8 percent in patients with solid tumors, 8.9 percent in patients with lymphoma, and 14.3 percent in patients with leukemia. The number of major comorbid conditions also significantly affected the mortality rate. Patients without any comorbidities had a 2.6 percent risk of dying, compared with 10.3 percent in patients with one comorbidity, 21.4 percent in patients with two comorbidities, 38.6 percent in patients with three comorbidities, and 50.6 percent in patients with four comorbidities.",
"   </p>",
"   <p>",
"    Patients with unexplained neutropenic fevers (fever but no clinical focus or pathogen documented) have higher rates of treatment success compared with those with documented infections (82 versus 62 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/30\">",
"     30",
"    </a>",
"    ]. Moreover, treatment successes among patients with solid tumors are more common than among those with hematologic malignancies (82 versus 56 percent).",
"   </p>",
"   <p>",
"    Factors that influence the risk of treatment failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link&amp;anchor=H608696459#H608696459\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\", section on 'Risk of treatment failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169494860\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective infection prevention strategies for low-risk neutropenic patients have focused upon the most common pathogens causing the infections, including pyogenic bacteria, viruses, and fungi. The risk for developing a neutropenic fever syndrome and experiencing serious complications should be evaluated in consultation with an infectious diseases specialist, considering patient-related, disease-related, and treatment-related factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H247552642\">",
"    <span class=\"h2\">",
"     Antibacterial prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroquinolone-based antibacterial prophylaxis has been effective in reducing febrile events and invasive gram-negative infections in high-risk neutropenic patients (",
"    <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Although randomized controlled studies in low-risk patients have demonstrated some protective effects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/48\">",
"     48",
"    </a>",
"    ], the number of low-risk patients requiring treatment in order to prevent one infection has been high [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/49\">",
"     49",
"    </a>",
"    ]. Given the increased costs, drug-related adverse effects, susceptibility to superinfection (such as Clostridium difficile infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/50\">",
"     50",
"    </a>",
"    ]), and selection for antimicrobial resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/51-53\">",
"     51-53",
"    </a>",
"    ], we do not recommend the routine use of antibacterial prophylaxis for low-risk patients for whom the duration of neutropenia (absolute neutrophil count [ANC] &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    is anticipated to be seven days or fewer. Our approach differs slightly from that of the Infectious Diseases Society of America (IDSA) and the American Society of Clinical Oncology (ASCO) because we consider high-risk patients to be those who are anticipated to have an ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (rather than &le;100",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    for &gt;7 days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9532986\">",
"     'Risk of serious complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with solid tumors who are receiving conventional chemotherapy are generally considered to be at low risk for complications of neutropenia, and therefore do",
"    <strong>",
"     not",
"    </strong>",
"    require antibacterial prophylaxis.",
"   </p>",
"   <p>",
"    Antibacterial prophylaxis for high-risk neutropenic patients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H247552649\">",
"    <span class=\"h2\">",
"     Antifungal prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for invasive fungal infection due to opportunistic yeasts, such as Candida spp, or molds, such as Aspergillus spp, is very low among patients for whom the anticipated duration of neutropenia (ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    is anticipated to be seven days or fewer. Accordingly, antifungal prophylaxis for patients with solid tumors or lymphoma undergoing conventional chemotherapy with or without concomitant immunotherapies is",
"    <strong>",
"     not",
"    </strong>",
"    recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. As described above for antibacterial prophylaxis, our approach differs slightly from that of the IDSA and ASCO because we consider high-risk patients to be those who are anticipated to have an ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (rather than &le;100",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    for &gt;7 days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9532986\">",
"     'Risk of serious complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Antifungal prophylaxis in high-risk patients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H247552693\">",
"    <span class=\"h3\">",
"     Pneumocystis prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most low-risk cancer patients do not require prophylaxis against Pneumocystis jirovecii (formerly P. carinii) pneumonia (PCP). The indications for PCP prophylaxis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H247552656\">",
"    <span class=\"h2\">",
"     Antiviral prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several preventive measures can be used to prevent viral infections in neutropenic patients. Hand hygiene and cough etiquette remain the most important methods for preventing the spread of respiratory virus infections in ambulatory low-risk cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H247552830\">",
"    <span class=\"h3\">",
"     HSV and VZV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral prophylaxis against herpes simplex virus (HSV) and varicella-zoster virus (VZV) is generally not used in low-risk patients since the rate of reactivation of these viruses is low in such patients. In contrast, antiviral prophylaxis with activity against HSV and VZV is used routinely in high-risk neutropenic patients (eg, patients receiving induction chemotherapy for acute leukemia, hematopoietic cell transplant recipients). This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link&amp;anchor=H1636049666#H1636049666\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\", section on 'HSV and VZV'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H247552837\">",
"    <span class=\"h3\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of influenza virus should be considered well in advance of the development of neutropenia. Annual immunization with a trivalent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    is recommended for all patients being treated for cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Although the optimal timing for such immunization has not been established, the vaccine is generally administered &gt;2 weeks before chemotherapy starts or, when circumstances dictate, between chemotherapy cycles and at least seven days after the last cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2\">",
"     2",
"    </a>",
"    ]. Annual immunization of all family members and other close contacts is also recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link&amp;anchor=H9#H9\">",
"     \"Immunizations in patients with cancer\", section on 'Influenza vaccine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemoprophylaxis to prevent influenza virus is indicated under certain circumstances. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link&amp;anchor=H17#H17\">",
"     \"Prevention of seasonal influenza in adults\", section on 'Indications for chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H247552851\">",
"    <span class=\"h3\">",
"     Hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid tumor and lymphoma patients receiving chemotherapy who have a history of previous hepatitis B virus infection are at risk of reactivation with a flare of hepatitis that may potentially result in hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/54\">",
"     54",
"    </a>",
"    ]. Patients with elevated circulating hepatitis B DNA or detectable levels of circulating hepatitis B surface antigen (HBsAg) are at particular risk. Those who have been infected and who have cleared the virus from the circulation and who have developed antibody to HBsAg or to hepatitis B core antigen are also at risk. Antiviral prophylaxis should be considered for such patients at risk for reactivation; when used, antiviral prophylaxis should be started one week before chemotherapy begins and continued for at least six months after the completion of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/7,54\">",
"     7,54",
"    </a>",
"    ]. This strategy can reduce the risk for reactivation from 24 to 53 percent to 0 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/55\">",
"     55",
"    </a>",
"    ]. The choice of agent is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1636049463\">",
"    <span class=\"h2\">",
"     Colony stimulating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Infectious Diseases Society of America (IDSA) guidelines recommend that the prophylactic use of colony stimulating factors (also known as myeloid growth factors or hematopoietic growth factors), such as granulocyte and granulocyte-macrophage colony stimulating factors (G-CSF and GM-CSF), be considered for patients in whom the anticipated risk of fever and neutropenia is &ge;20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/37/22106/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1711380062\">",
"    <span class=\"h2\">",
"     Infection control precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection control precautions for patients who are hospitalized with neutropenic fever are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link&amp;anchor=H875811313#H875811313\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\", section on 'Infection control precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443613796\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations below apply to patients who are at low risk for complications of neutropenic fever. The treatment and prevention of neutropenic fever in high-risk patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80105007\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer patients receiving cytotoxic antineoplastic therapy sufficient to adversely affect myelopoiesis and the developmental integrity of the gastrointestinal mucosa are at risk for invasive infection due to colonizing bacteria or fungi that translocate across intestinal mucosal surfaces. Since the magnitude of the neutrophil-mediated component of the inflammatory response may be muted in neutropenic patients, an elevated body temperature may be the earliest and only sign of infection. It is critical to recognize neutropenic fever early and to initiate empiric systemic antibacterial therapy promptly in order to avoid progression to a sepsis syndrome and possibly death. (See",
"      <a class=\"local\" href=\"#H1169494774\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is crucial that there be an assessment of the risk of serious complications in patients with neutropenic fever, since this assessment will dictate the approach to therapy, including the need for inpatient admission, IV antibiotics, and prolonged hospitalization. Low-risk patients are those in whom the duration of neutropenia (absolute neutrophil count [ANC] &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      is expected to be seven days or fewer, and those with no comorbidities or evidence of significant hepatic or renal dysfunction. Most patients receiving chemotherapy for solid tumors are considered to be low-risk. (See",
"      <a class=\"local\" href=\"#H9532986\">",
"       'Risk of serious complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The commonest bloodstream isolates in low-risk patients are gram-positive cocci (in almost one-half the cases), with the majority being due to coagulase-negative staphylococci or S. aureus. Just over one-third of bloodstream isolates are gram-negative bacilli. Fungal infections are uncommon in low-risk patients with neutropenic fever. Reactivation of herpes simplex virus and varicella-zoster virus is also rare in low-risk patients. The Table lists the range of pathogens found in both high-risk and low-risk patients with chemotherapy-induced neutropenia (",
"      <a class=\"graphic graphic_table graphicRef63465 \" href=\"UTD.htm?0/44/718\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1169494934\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80104991\">",
"    <span class=\"h2\">",
"     Initial assessment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever in a neutropenic patient should be considered a medical emergency. Empiric broad-spectrum antibacterial therapy should be initiated immediately after blood cultures have been obtained and before any other investigations have been completed. (See",
"      <a class=\"local\" href=\"#H1636049913\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H376946545\">",
"       'Timing of antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients who have received systemic anti-cancer therapy within the previous six weeks and who present to an emergency department with a systemic inflammatory response syndrome should be presumed to have a neutropenic sepsis syndrome until proven otherwise. Empiric broad-spectrum antimicrobial therapy should be administered within",
"      <strong>",
"       60 minutes",
"      </strong>",
"      of presentation for patients presenting with neutropenic fever and a sepsis syndrome, severe sepsis, or septic shock (",
"      <a class=\"graphic graphic_algorithm graphicRef57616 \" href=\"UTD.htm?35/16/36100\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H453916950\">",
"       'Risk of neutropenia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H376946545\">",
"       'Timing of antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic evaluation should be obtained promptly (",
"      <a class=\"graphic graphic_table graphicRef50509 \" href=\"UTD.htm?23/55/24444\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"       \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3708499\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although gram-positive bacteria are the most frequent pathogens identified during neutropenic fever episodes, it is important to cover broadly for gram-negative pathogens because of their virulence and association with sepsis. For the initial empiric oral antibacterial regimen for low-risk patients with neutropenic fever, we recommend a combination of a fluoroquinolone (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      750 mg orally twice daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      750 mg orally once daily) and a beta-lactam agent such as amoxicillin-clavulanic acid (500",
"      <span class=\"nowrap\">",
"       mg/125",
"      </span>",
"      mg orally three times daily) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients receiving fluoroquinolone-based antibacterial prophylaxis should",
"      <strong>",
"       not",
"      </strong>",
"      receive a fluoroquinolone-based initial empiric antibacterial therapy. (See",
"      <a class=\"local\" href=\"#H1169494839\">",
"       'Initial regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who meet",
"      <strong>",
"       all",
"      </strong>",
"      criteria for being at low risk for complications of neutropenic fever can be treated as outpatients, following either a brief period of observation or a short hospital admission. We favor monitoring patients for at least four hours after the initial dose of antibiotics before sending them home. (See",
"      <a class=\"local\" href=\"#H247552555\">",
"       'Site of care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients deemed eligible for outpatient management must be able to access medical care 24 hours daily, seven days per week, and should be able to reach the medical facility within one hour should the clinical condition worsen. Fever recrudescence or new signs of infection should mandate admission to hospital for IV antibacterial therapy. (See",
"      <a class=\"local\" href=\"#H80104940\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80104999\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We do not recommend antibacterial prophylaxis for low-risk patients (eg, patients with solid tumors who are receiving conventional chemotherapy) for whom the duration of neutropenia (ANC &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      is anticipated to be seven days or fewer (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H247552642\">",
"       'Antibacterial prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not recommend antifungal prophylaxis for low-risk patients for whom the anticipated duration of neutropenia (ANC &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      is anticipated to be seven days or fewer (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H247552649\">",
"       'Antifungal prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107054675\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate Inc. would like to acknowledge Dr. Gregory K Robbins and Dr. Richard A Larson, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/1\">",
"      Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/2\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/3\">",
"      Link H, B&ouml;hme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82 Suppl 2:S105.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2012. file://www.nccn.org (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/5\">",
"      Infectious Diseases Society of Taiwan, Hematology Society of Taiwan, Medical Foundation in Memory Dr. Deh-Lin Cheng, et al. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect 2005; 38:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/6\">",
"      Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis 2004; 39 Suppl 1:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/7\">",
"      Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31:794.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on February 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/9\">",
"      Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/10\">",
"      Kamana M, Escalante C, Mullen CA, et al. Bacterial infections in low-risk, febrile neutropenic patients. Cancer 2005; 104:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/11\">",
"      Paesmans M, Klastersky J, Maertens J, et al. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer 2011; 19:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/12\">",
"      McKenzie H, Hayes L, White K, et al. Chemotherapy outpatients' unplanned presentations to hospital: a retrospective study. Support Care Cancer 2011; 19:963.",
"     </a>",
"    </li>",
"    <li>",
"     Bell MS, Scullen P, McParlan D, et al. Neutropenic sepsis guidelines. Northern Ireland Cancer Network, Belfast 2010. p. 1-11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/14\">",
"      Sickles EA, Young VM, Greene WH, Wiernik PH. Pneumonia in acute leukemia. Ann Intern Med 1973; 79:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/15\">",
"      Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/16\">",
"      American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/17\">",
"      Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/18\">",
"      Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/19\">",
"      Sepkowitz KA. Treatment of patients with hematologic neoplasm, fever, and neutropenia. Clin Infect Dis 2005; 40 Suppl 4:S253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/20\">",
"      Lazarus HM, Creger RJ, Gerson SL. Infectious emergencies in oncology patients. Semin Oncol 1989; 16:543.",
"     </a>",
"    </li>",
"    <li>",
"     Chemotherapy services in England: Ensuring quality and safety. National Chemotherapy Advisory Group, London 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/22\">",
"      Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 2005; 40 Suppl 4:S246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/23\">",
"      Viscoli C, Castagnola E. Planned progressive antimicrobial therapy in neutropenic patients. Br J Haematol 1998; 102:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/24\">",
"      Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005; 40 Suppl 4:S240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/25\">",
"      Pagano L, Caira M, Nosari A, et al. Etiology of febrile episodes in patients with acute myeloid leukemia: results from the Hema e-Chart Registry. Arch Intern Med 2011; 171:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/26\">",
"      Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/27\">",
"      Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/28\">",
"      de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 Suppl 5:v252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/29\">",
"      Teuffel O, Ethier MC, Alibhai SM, et al. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol 2011; 22:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/30\">",
"      Vidal L, Paul M, Ben-Dor I, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2004; :CD003992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/31\">",
"      Freifeld AG, Sepkowitz KA. No place like home? Outpatient management of patients with febrile neutropenia and low risk. J Clin Oncol 2011; 29:3952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/32\">",
"      Elting LS, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008; 26:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/33\">",
"      Hendricks AM, Loggers ET, Talcott JA. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol 2011; 29:3984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/34\">",
"      Freifeld A, Sankaranarayanan J, Ullrich F, Sun J. Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer 2008; 16:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/35\">",
"      Talcott JA, Yeap BY, Clark JA, et al. Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol 2011; 29:3977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/36\">",
"      Innes HE, Smith DB, O'Reilly SM, et al. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 2003; 89:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/37\">",
"      Innes H, Billingham L, Gaunt C, et al. Management of febrile neutropenia in the United Kingdom: time for a national trial? Br J Cancer 2005; 93:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/38\">",
"      Girmenia C, Russo E, Carmosino I, et al. Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia. Ann Hematol 2007; 86:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/39\">",
"      Sebban C, Dussart S, Fuhrmann C, et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 2008; 16:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/40\">",
"      Bow EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol 2009; 46:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/41\">",
"      Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/42\">",
"      Klastersky J, Cappel R, Debusscher L. Evaluation of gentamicin with carbenicillin in infections due to gram-negative bacilli. Curr Ther Res Clin Exp 1971; 13:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/43\">",
"      Klastersky J. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy? J Antimicrob Chemother 2009; 63 Suppl 1:i14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/44\">",
"      Gram-negative bacteremia, clinical, laboratory and therapeutic observations. Arch Intern Med 1962; 110:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/45\">",
"      Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/46\">",
"      Bow EJ. Point: fluoroquinolone-based antibacterial chemoprophylaxis in neutropenic cancer patients works for defined outcomes in defined populations, but must be used wisely. J Natl Compr Canc Netw 2004; 2:433.",
"     </a>",
"    </li>",
"    <li>",
"     Bow EJ. Prophylaxis. In: Managing Infections in Patients with Hematological Malignancies, Kleinberg M (Ed), Humana Press, 2009. p.259.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/48\">",
"      Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/49\">",
"      Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005; 353:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/50\">",
"      P&eacute;pin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/51\">",
"      Kern WV, Andriof E, Oethinger M, et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/52\">",
"      Carratal&aacute; J, Fern&aacute;ndez-Sevilla A, Tubau F, et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/53\">",
"      Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 2011; 24:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/54\">",
"      Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010; 25:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/37/22106/abstract/55\">",
"      Firpi RJ, Nelson DR. Viral hepatitis: manifestations and management strategy. Hematology Am Soc Hematol Educ Program 2006; :375.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13951 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22106=[""].join("\n");
var outline_f21_37_22106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H443613796\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1169494774\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105832552\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9532962\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9532970\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9532978\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9532986\">",
"      RISK OF SERIOUS COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1169494934\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H453916929\">",
"      INITIAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453916950\">",
"      Risk of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453917003\">",
"      High-risk versus low-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453917078\">",
"      Risk of sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H453917156\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1169494817\">",
"      EMPIRIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1636049913\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376946545\">",
"      - Timing of antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1636051077\">",
"      - Spectrum of coverage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1169494839\">",
"      Initial regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H247552555\">",
"      Site of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H80104940\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1169494853\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H120313815\">",
"      Colony stimulating factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477726908\">",
"      MYELOID RECONSTITUTION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H344318\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1169494860\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H247552642\">",
"      Antibacterial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H247552649\">",
"      Antifungal prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H247552693\">",
"      - Pneumocystis prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H247552656\">",
"      Antiviral prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H247552830\">",
"      - HSV and VZV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H247552837\">",
"      - Influenza",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H247552851\">",
"      - Hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1636049463\">",
"      Colony stimulating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1711380062\">",
"      Infection control precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H443613796\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H80105007\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H80104991\">",
"      Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3708499\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H80104999\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107054675\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13951\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13951|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/16/36100\" title=\"algorithm 1\">",
"      Neutropenic fever sepsis algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?40/56/41856\" title=\"algorithm 2\">",
"      Neutropenic fever initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13951|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/26/40364\" title=\"table 1\">",
"      High-risk patients with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/44/718\" title=\"table 2\">",
"      Pathogens in neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/55/24444\" title=\"table 3\">",
"      Diagnostic evaluation fever and neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=related_link\" title=\"calculator 1\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?14/34/14881?source=related_link\" title=\"calculator 2\">",
"      Calculator: Multinational Association for Supportive Care in Cancer (MASCC) risk index for patients with neutropenic fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=related_link\">",
"      Diagnostic approach to the adult presenting with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=related_link\">",
"      Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=related_link\">",
"      Risk assessment of adults with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_37_22107="Continuous birth control PI";
var content_f21_37_22107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hormonal birth control pills that are packaged for continuous dosing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Brand name",
"      </td>",
"      <td class=\"subtitle1\">",
"       Number of pills in pack",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Seasonale*",
"      </td>",
"      <td>",
"       120",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Quasense*",
"      </td>",
"      <td>",
"       120",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Jolessa*",
"      </td>",
"      <td>",
"       120",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Seasonique&bull;",
"      </td>",
"      <td>",
"       120",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lybrel&Delta;",
"      </td>",
"      <td>",
"       365",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Taking continuous hormonal birth control means that you will have less frequent menstrual periods. However, many women have irregular spotting or bleeding when starting this regimen. This spotting and bleeding may be inconvenient but does not mean that you are more likely to get pregnant (unless you miss a dose of pills).",
"    <div class=\"footnotes\">",
"     * These pills are designed so that you will have a menstrual period once every 3 months. The pack includes 83 pills that contain two hormones (estrogen and progestin) and 7 pills that are placebo (sugar) pills. During the placebo pill week, you will have menstrual bleeding.",
"     <br>",
"      &bull; Seasonique includes 83 pills that contain two hormones (estrogen and progestin) and 7 pills that contain one hormone (estrogen). This regimen may be helpful for women who develop headaches related to a low estrogen level during the last week of pills.",
"      <br>",
"       &Delta; Lybrel includes 365 pills, so you will not have menstrual bleeding for a full year.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22107=[""].join("\n");
var outline_f21_37_22107=null;
var title_f21_37_22108="Lung transplant pathogens";
var content_f21_37_22108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common fungal pathogens in lung transplantation and their usual clinical manifestations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Pathogen",
"      </td>",
"      <td class=\"subtitle1\">",
"       Usual clinical manifestation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       <em>",
"        Aspergillus",
"       </em>",
"       spp",
"      </td>",
"      <td>",
"       Airway colonization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tracheobronchitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pulmonary disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       <em>",
"        Blastomycosis",
"       </em>",
"      </td>",
"      <td>",
"       Pulmonary disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disseminated disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Candida",
"       </em>",
"       spp",
"      </td>",
"      <td>",
"       Candidemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Coccidioidomycosis",
"      </td>",
"      <td>",
"       Pulmonary disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disseminated disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       <em>",
"        Cryptococcus neoformans",
"       </em>",
"      </td>",
"      <td>",
"       Pulmonary disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Meninigitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cellulitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Dematiaceous molds*",
"      </td>",
"      <td>",
"       Skin and soft tissue infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Brain abscess",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <em>",
"        Fusarium",
"       </em>",
"       spp",
"      </td>",
"      <td>",
"       Skin and soft tissue infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Histoplasmosis",
"      </td>",
"      <td>",
"       Fever of unknown origin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pulmonary disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disseminated disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       <em>",
"        Scedosporium",
"       </em>",
"       spp",
"      </td>",
"      <td>",
"       Pulmonary disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disseminated disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Zygomycetes",
"      </td>",
"      <td>",
"       Pulmonary disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rhinocerebral infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disseminated disease",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *",
"     <em>",
"      Exophiala",
"     </em>",
"     ,",
"     <em>",
"      Alternaria",
"     </em>",
"     ,",
"     <em>",
"      Curvularia",
"     </em>",
"     ,",
"     <em>",
"      Dactylaria",
"     </em>",
"     ,",
"     <em>",
"      Cladophialophora",
"     </em>",
"     and others.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008; 14:211. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22108=[""].join("\n");
var outline_f21_37_22108=null;
var title_f21_37_22109="Thyrotoxicosis child";
var content_f21_37_22109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of thyrotoxicosis in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Synonyms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antibody tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        RAI",
"       </td>",
"       <td class=\"subtitle1\">",
"        Thyroid exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Thyroid gland hyperfunction (increased synthesis of thyroid hormones)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Graves' disease",
"       </td>",
"       <td>",
"        <p>",
"         Hyperthyroid goiter",
"        </p>",
"        von Basedow's disease",
"       </td>",
"       <td>",
"        Thyrotropin receptor-stimulating antibodies (TRS-Ab)",
"       </td>",
"       <td>",
"        TRS-Ab positive; TPO-Ab positive or negative; TBII positive",
"       </td>",
"       <td>",
"        High, diffuse",
"       </td>",
"       <td>",
"        Symmetric nontender goiter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multinodular hyperthyroid goiter",
"       </td>",
"       <td>",
"        Toxic multinodular goiter",
"       </td>",
"       <td>",
"        Autonomous overproduction of thyroid hormone by nodules",
"       </td>",
"       <td>",
"        All negative",
"       </td>",
"       <td>",
"        Normal or high, multifocal",
"       </td>",
"       <td>",
"        Nodular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autonomous nodule",
"       </td>",
"       <td>",
"        <p>",
"         Plummer's disease",
"        </p>",
"        Toxic nodule",
"       </td>",
"       <td>",
"        Same",
"       </td>",
"       <td>",
"        All negative",
"       </td>",
"       <td>",
"        High, single focus; rest of gland suppressed",
"       </td>",
"       <td>",
"        Single nodule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TSH-producing pituitary adenoma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Autonomous overproduction of TSH",
"       </td>",
"       <td>",
"        All negative",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Normal or symmetric goiter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pituitary resistance to thyroid hormone",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Overproduction of TSH",
"       </td>",
"       <td>",
"        All negative",
"       </td>",
"       <td>",
"        High, diffuse",
"       </td>",
"       <td>",
"        Symmetric goiter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Thyrotoxic phase of thyroiditis (excess secretion of preformed thyroid hormones)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thyrotoxic phase of chronic lymphocytic (Hashimoto's) thyroiditis",
"       </td>",
"       <td>",
"        <p>",
"         Hashitoxicosis",
"        </p>",
"        Lymphadenoid goiter",
"       </td>",
"       <td>",
"        Autoimmune; release of preformed hormone. Predominantly women.",
"       </td>",
"       <td>",
"        TPO-Ab positive; thyroglobulin positive; TRS-Ab positive or negative",
"       </td>",
"       <td>",
"        Low in majority, but can be elevated if TRS-Ab positive; inhomogeneous pattern",
"       </td>",
"       <td>",
"        Firm goiter, sometimes tender",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subacute lymphocytic thyroiditis",
"       </td>",
"       <td>",
"        <p>",
"         Painless sporadic thyroiditis",
"        </p>",
"        Silent thyroiditis",
"       </td>",
"       <td>",
"        Autoimmune; release of preformed hormone. May also be associated with drugs (IFN-alpha, IL-2, lithium).",
"       </td>",
"       <td>",
"        TPO-Ab positive",
"       </td>",
"       <td>",
"        Low (during thyrotoxic phase)",
"       </td>",
"       <td>",
"        Firm nontender, mildly enlarged thyroid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subacute granulomatous thyroiditis",
"       </td>",
"       <td>",
"        <p>",
"         Subacute thyroiditis",
"        </p>",
"        <p>",
"         Painful subacute thyroiditis",
"        </p>",
"        <p>",
"         de Quervain's thyroiditis",
"        </p>",
"        Granulomatous giant cell thyroiditis",
"       </td>",
"       <td>",
"        Viral; release of preformed hormone",
"       </td>",
"       <td>",
"        TPO-Ab negative; elevated ESR",
"       </td>",
"       <td>",
"        Low (during thyrotoxic phase)",
"       </td>",
"       <td>",
"        Painful goiter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Drug-induced thyrotoxicosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Factitous thyroiditis",
"       </td>",
"       <td>",
"        Thyrotoxicosis factitia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Low TSH",
"       </td>",
"       <td>",
"        Low or absent",
"       </td>",
"       <td>",
"        No goiter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iodine-induced hyperthyroidism",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Underlying multinodular goiter; thyroid hormone release triggered by exposure to iodine (eg, contrast agents, amiodarone)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Often multinodular",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TRS-Ab: thyrotropin-receptor stimulating antibodies; TPO-Ab: thyroid peroxidase antibodies; TBII: thyrotropin binding inhibitor immunoglobulin.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22109=[""].join("\n");
var outline_f21_37_22109=null;
var title_f21_37_22110="Contents: Postpartum issues";
var content_f21_37_22110=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Postpartum issues",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Postpartum issues",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Breastfeeding",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/39/42616\">",
"           Breastfeeding: Parental education and support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/15/17658\">",
"           Common problems of breastfeeding and weaning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/47/32505\">",
"           Infant benefits of breastfeeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/53/43864\">",
"           Maternal nutrition during lactation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/36/6727\">",
"           Nutritional composition of human milk for full-term infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/1/32794\">",
"           Principles of medication use during lactation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/53/38745\">",
"           Use of psychotropic medications in breastfeeding women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrine disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/38/9833\">",
"           Causes of hypopituitarism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/47/14073\">",
"           Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/62/37866\">",
"           Medical management and follow-up of gestational diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/51/16186\">",
"           Overview of thyroid disease in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/15/248\">",
"           Postpartum thyroiditis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/5/28761\">",
"           Approaches to reduction of maternal mortality in resource-limited settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/59/40888\">",
"           Overview of maternal mortality",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/30/39402\">",
"           Overview of postpartum care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/8/24713\">",
"           Postpartum and postabortion contraception",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Heart disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/62/18410\">",
"           Peripartum cardiomyopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemorrhage",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/4/16455\">",
"           Management of hematomas incurred as a result of obstetrical delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/44/27336\">",
"           Management of postpartum hemorrhage at cesarean delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/60/41929\">",
"           Management of postpartum hemorrhage at vaginal delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/38/42600\">",
"           Overview of postpartum hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29367\">",
"           Peripartum hysterectomy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/16/18698\">",
"           Group B streptococcal infection in neonates and young infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/35/31290\">",
"           Overview of control measures to prevent surgical site infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/11/39097\">",
"           Postpartum endometritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/41/6807\">",
"           Septic pelvic thrombophlebitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Newborn issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/16/18698\">",
"           Group B streptococcal infection in neonates and young infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/46/41705\">",
"           Neonatal circumcision: Risks and benefits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26346\">",
"           Neonatal resuscitation in the delivery room",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/57/15256\">",
"           Techniques for neonatal circumcision",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psychiatric issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/11/20666\">",
"           Postpartum blues and depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/53/38745\">",
"           Use of psychotropic medications in breastfeeding women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33479\">",
"           Acute kidney injury (acute renal failure) in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36826\">",
"           Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/31/42490\">",
"           Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-32DD5EC3D0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f21_37_22110=[""].join("\n");
var outline_f21_37_22110=null;
var title_f21_37_22111="Pinhole occluder";
var content_f21_37_22111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pinhole occluder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pinhole occluder is a simple way to focus light, as in a pinhole camera, temporarily removing the effects of refractive errors such as myopia in order to assess visual acuity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_37_22111=[""].join("\n");
var outline_f21_37_22111=null;
